On this page
Quick Reference
Overview and Recommendations
Background
- •Infective endocarditis (IE) is a microbial infection of the endocardial surface, most frequently involving native or , the mural endocardium, or cardiac implantable electronic devices. The global incidence ranges from 1 to 2 per 100,000 person-years in high-income countries and exceeds 10 per 100,000 in regions with high prevalence. In the United States, age-adjusted incidence is approximately 15 per 100,000, with 40,000 to 50,000 cases annually. IE carries a 1-year mortality of approximately 30%, which has not improved in the past three decades despite advances in diagnostics and surgery.
- •The epidemiology of IE has shifted dramatically over the past two decades. The median age at diagnosis has risen to 67-75 years, and healthcare-associated IE now accounts for 25-35% of cases in high-income countries, driven by intravascular catheters, hemodialysis, and cardiac devices. Prosthetic valve endocarditis (PVE) complicates 1-2% of implantations per year, and transcatheter (TAVR)-associated IE has a cumulative incidence of 2.5% at 2 years. The opioid epidemic has also fueled a disproportionate rise in injection drug use-associated IE (IDU-IE), with rural areas experiencing a 13-fold increase from 2003 to 2016.
- •IE is classified along three axes that directly inform empiric therapy and urgency: temporal course (acute, days, subacute, weeks, chronic, months), mode of acquisition (community-acquired, healthcare-associated, or injection drug use-related), and anatomic site (native valve, prosthetic valve, or cardiac implantable electronic device). Each category carries a distinct microbiologic profile. Acute IE is most often caused by *
- and presents with rapid valve destruction and sepsis; subacute IE is typically due to viridans group streptococci or enterococci and presents indolently. Healthcare-associated IE is enriched for MRSA and enterococci; IDU-IE is dominated by S. aureus (>60%) with a high incidence of right-sided (tricuspid valve) involvement.
- •Gram-positive cocci cause >80% of all IE cases. S. aureus is the single most common cause in the developed world (25-40% of cases), with methicillin-resistant S. aureus (MRSA) accounting for 30-50% of staphylococcal IE in healthcare-associated settings. Viridans group streptococci (15-25%), Enterococcus faecalis (10-15%), and coagulase-negative staphylococci (CoNS) are the other major pathogens. Culture-negative endocarditis accounts for 5-10% of cases and is most frequently due to Bartonella species, Coxiella burnetii, or prior antibiotic exposure. The HACEK group (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) causes 5-10% of community-acquired IE, often associated with prior dental disease.
Evaluation
- •Suspect IE in any patient with fever and a new or changing heart murmur, especially in the presence of risk factors such as , prior IE, injection drug use, congenital heart disease, or hemodialysis. The presentation spans a spectrum from acute, fulminant sepsis (high fever, rigors, rapid hemodynamic deterioration) to an indolent, low-grade febrile illness (night sweats, anorexia, weight loss). Fever is present in >90% of patients but may be absent in the elderly, immunocompromised, or those with prior antibiotic exposure.
- •Ask about predisposing conditions: prosthetic valves, implantable cardiac devices, prior IE, rheumatic heart disease, degenerative valve disease, congenital heart disease, recent dental or surgical procedures, injection drug use, or central venous catheters. Also ask about symptoms of embolic phenomena: sudden neurological deficit (stroke), flank pain (splenic or renal infarction), chest pain or hemoptysis (septic pulmonary emboli in right-sided IE), or limb ischemia.
- •Examine for the classic peripheral stigmata: Osler nodes (painful, erythematous nodules on finger/toe pads), Janeway lesions (painless, hemorrhagic macules on palms/soles), splinter hemorrhages (linear, dark streaks under nails), Roth spots (retinal hemorrhages with pale centers on fundoscopy), and conjunctival petechiae. A cardiac murmur is present in approximately 85% of patients with left-sided IE; a new or changing murmur is a classic finding. Right-sided IE (tricuspid valve) may lack a murmur or produce a soft, blowing systolic murmur that increases with inspiration.
- •Order at least three sets of blood cultures from separate venipuncture sites before starting antibiotics, ideally over 30-60 minutes. Each set should include one aerobic and one anaerobic bottle. The single most important microbiologic finding is persistent bacteremia: two or more positive cultures drawn >12 hours apart, or three or more of four positive cultures with the first and last drawn ≥1 hour apart. In S. aureus bacteremia, a short time to positivity (typically ≤12-14 hours) increases the likelihood of IE and lowers the threshold for echocardiography.
- •Apply the modified Duke criteria to assign patients to definite, possible, or rejected IE categories. The major criteria are: (1) persistent bacteremia with a typical IE pathogen (viridans group streptococci, S. aureus, or enterococci) from ≥2 blood cultures, or a single positive culture for Coxiella burnetii or anti-phase I IgG ≥1:800; and (2) echocardiographic evidence of vegetation, abscess, or new partial dehiscence of a prosthetic valve. Minor criteria include predisposing heart condition or injection drug use, fever ≥38°C, vascular phenomena (arterial emboli, septic pulmonary infarcts, ), immunologic phenomena (glomerulonephritis, Osler nodes, Roth spots), and microbiologic evidence not meeting major criteria.
- •Perform first in all patients with suspected IE. TTE has a sensitivity of 50-65% for native valve vegetations but only 25-35% for prosthetic valve endocarditis (PVE). is the test of choice when clinical suspicion persists despite a negative TTE, when prosthetic material is present, or when TTE is nondiagnostic. TEE increases sensitivity for native valve disease to 90-95% and for PVE to 85-90%, and it is superior for detecting perivalvular abscesses, leaflet perforations, and prosthetic dehiscence.
- •When echocardiography is inconclusive, especially in PVE or cardiac implantable electronic device infections, obtain , which has a sensitivity of 70-85% and specificity of 80-90% for PVE. provides complementary anatomic detail, identifying perivalvular abscesses, pseudoaneurysms, and fistulae with high accuracy.
- •Consider in all patients with suspected IE or neurologic symptoms. Cerebral embolic events are found in 44% of patients and can upgrade the Duke classification from possible to definite. In patients with S. aureus IE, a low threshold for cerebral imaging is warranted given the high embolic risk.
- •If blood cultures remain negative at 48-72 hours (culture-negative endocarditis), initiate a structured workup: serology for C. burnetii (phase I IgG ≥1:800 is diagnostic), Bartonella species, and Brucella species. Consider of excised valvular tissue or embolic material, or (Karius test), which can identify pathogens in 30-50% of culture-negative cases. Send valvular tissue for both culture and PCR if surgery is performed.
- •Establish a multidisciplinary (cardiologist, cardiac surgeon, infectious disease specialist) to adjudicate all cases and direct management. Team-based care reduces in-hospital mortality from 22.1% to 14.3% (NNT = 13) and shortens time to surgery.
- •The differential diagnosis includes nonbacterial thrombotic endocarditis (marantic endocarditis, associated with malignancy, SLE, antiphospholipid syndrome), rheumatic fever (migratory arthritis, chorea, elevated ASO titers), , acute pericarditis, systemic vasculitis ( , ANCA-associated vasculitis), and septic emboli from an extracardiac source (e.g., suppurative thrombophlebitis).
Management
- •Classify severity at presentation based on hemodynamic stability, presence of acute valve regurgitation, and embolic risk. Patients with septic shock, (NYHA class III/IV), or large vegetations (>10 mm) with embolic events require immediate ICU admission and urgent cardiothoracic surgery consultation. Stable patients can be managed on a ward with continuous telemetry monitoring.
- •Initiate empiric antibiotics immediately after obtaining blood cultures. For community-acquired native valve endocarditis in a patient without injection drug use, start 2 g IV every 4 hours plus 2 g IV every 12 hours. This dual β-lactam regimen covers streptococci and provides synergistic activity against Enterococcus faecalis.
- •For healthcare-associated or prosthetic valve endocarditis, or in persons who inject drugs (PWID), start 15-20 mg/kg IV every 8-12 hours (target trough 15-20 µg/mL) plus 2 g IV every 8 hours to cover MRSA and Gram-negative bacilli.
- •In patients with (non-anaphylactic), cefazolin 2 g IV every 8 hours can replace ampicillin for streptococcal coverage, but vancomycin remains first-line for MRSA. For culture-negative endocarditis (e.g., after prior antibiotics, or suspected Bartonella, Coxiella burnetii), add 100 mg IV every 12 hours plus hydroxychloroquine for chronic Q fever, or follow specific PCR-directed therapy.
- •Do NOT use aminoglycosides routinely as adjunctive therapy for E. faecalis IE. The meta-analysis by Prosty et al. (2024) found no difference in clinical cure with gentamicin-based regimens versus ceftriaxone-based regimens, but gentamicin significantly increased nephrotoxicity (RR 2.1, 95% CI 1.3-3.4). The regimen of choice is ampicillin 2 g IV every 4 hours plus ceftriaxone 2 g IV every 12 hours for 6 weeks.
- •For MRSA IE, use at 8-10 mg/kg IV every 24 hours (not 6 mg/kg) because the higher dose improves the area under the curve to MIC ratio, reducing the risk of treatment-emergent resistance and CPK elevation. Monitor CPK weekly; discontinue daptomycin if CPK rises >5× the upper limit of normal with symptoms or >10× without symptoms.
- •Obtain a TEE in all patients with S. aureus bacteremia (even without clinical signs of IE) to rule out valvular vegetations. Draw daily blood cultures until they clear; persistent positivity after 48-72 hours of targeted therapy is an independent predictor of mortality and mandates a search for an undrained focus or reconsideration of surgical intervention.
- •The POET trial (2019) demonstrated that after an initial 10-day course of IV antibiotics, switching to oral therapy (e.g., 1 g PO three times daily, or 600 mg PO twice daily for MRSA) is noninferior to continued IV therapy in patients with left-sided IE who are clinically stable and have no uncontrolled heart failure, no perivalvular abscess, and no prosthetic valve dehiscence. Eligible patients for oral step-down must be afebrile for ≥24 hours, hemodynamically stable, have negative blood cultures for ≥48 hours, have no undrained abscess, an intact GI tract, and an available oral regimen with ≥80% bioavailability.
- •For patients who do not meet oral step-down criteria, is an alternative. The OPAT-GAMES criteria safely identify candidates: no cirrhosis, no severe central nervous system emboli, and a stable social situation. Administer ampicillin-ceftriaxone via elastomeric pump (41°C stable for 24 hours) or a peripherally inserted central catheter.
- •Early surgical consultation is mandatory for any patient with IE and a surgical indication. The randomized EASE trial (2012) demonstrated that early surgery (within 48 hours) in patients with left-sided IE, severe valve disease, and large vegetations (>10 mm) reduced the composite endpoint of in-hospital death or embolic events from 50% to 23% (absolute risk reduction 27%, NNT = 4) compared with conventional care.
- •Indications for urgent/emergent surgery include: (1) acute severe aortic or causing heart failure, (2) persistent bacteremia despite 5-7 days of appropriate antibiotics, (3) recurrent emboli despite therapy, (4) large vegetation >10 mm with prior embolic event, (5) prosthetic valve dehiscence or obstruction, and (6) fungal IE. For septic emboli to the brain, surgery should be delayed at least 4 weeks after the neurological event unless the abscess requires immediate drainage.
- •Monitor for complications: embolic stroke (15-35%), splenic infarction (10-20%), splenic abscess (3-5%), renal infarction (5%), mycotic aneurysm (5%), heart failure (30-60%), perivalvular abscess (10-40% in PVE), and new conduction abnormalities (suggest abscess extension into the interventricular septum). Obtain dedicated imaging (CT or MRI) if splenic or renal infarction is suspected. Early angiographic screening is warranted in patients with persistent headache or focal neurologic deficits due to risk of mycotic aneurysm rupture (mortality >50%).
- •Manage acute kidney injury (AKI) by avoiding nephrotoxic antibiotics when possible. Aminoglycoside-induced AKI occurs in 15-25% of treated patients; the incidence is nearly halved with ampicillin-ceftriaxone versus ampicillin-gentamicin. Vancomycin therapy targeting an AUC/MIC ratio >400 reduces nephrotoxicity compared to trough-based dosing.
- •Provide multimodal pain management. For moderate-to-severe pain in opioid-naïve patients, use 2-4 mg IV every 2-4 hours PRN. For post-surgical pain, patient-controlled analgesia with IV is effective. For persons who inject drugs with opioid tolerance, the required dose is often 3-5× the standard dose; consult addiction medicine or pain management. Adjunctive non-opioid agents, acetaminophen 1000 mg PO every 6 hours, gabapentin 300-600 mg PO three times daily, can reduce opioid requirements.
- •Initiate early mobilization as soon as hemodynamic stability is achieved (typically within 48 hours of extubation) to reduce muscle wasting and shorten hospital length of stay. Provide structured physical therapy including range-of-motion exercises, progressive ambulation, and inspiratory muscle training. Refer to comprehensive cardiac rehabilitation after valve surgery, beginning 4-6 weeks post-operatively.
- •For patients with opioid use disorder, implement protocol-driven withdrawal management (methadone or buprenorphine initiation; adjunctive clonidine) to prevent against medical advice discharge. Untreated withdrawal is a leading cause of treatment abandonment.
- •Avoid corticosteroids in IE, they are associated with a 2-fold increase in mortality. Hold all anticoagulation unless the patient has a mechanical valve; for mechanical valves, continue with INR monitoring due to the higher risk of hemorrhagic conversion in septic emboli.
- •Long-term suppressive antimicrobial therapy (SAT), typically with oral , , or , reduces relapse in patients with unresectable prosthetic material from 40% to 12% over 2 years (NNT = 4). Consider SAT in patients with prosthetic valves who are not candidates for valve replacement.
Board Review — High Yield
- •Modified Duke criteria, The diagnostic gold standard for IE. Major criteria: persistent bacteremia with typical pathogen + echocardiographic vegetation/abscess. Minor criteria: predisposing condition, fever, vascular/immunologic phenomena, microbiology.
- •Osler nodes vs. Janeway lesions, Osler nodes are painful, erythematous nodules on finger/toe pads (immune complex deposition). Janeway lesions are painless, hemorrhagic macules on palms/soles (septic emboli).
- •Staphylococcus aureus, The single most common cause of IE (25-40%), particularly aggressive in healthcare-associated and IDU-related cases. MRSA accounts for 30-50% in healthcare settings. Causes acute valve destruction and requires early surgery consultation.
- •Ampicillin + Ceftriaxone for E. faecalis, First-line regimen for enterococcal IE. Equivalent efficacy to ampicillin + gentamicin but significantly less nephrotoxicity (6% vs 24%; NNT = 6).
- •POET trial, After 10 days of IV therapy, switching to oral antibiotics (amoxicillin, linezolid, etc.) is noninferior to continued IV therapy in stable patients with left-sided IE. Validated in real-world cohorts including POET-ineligible subgroups.
- •EASE trial, Early surgery (within 48 hours) in patients with left-sided IE, severe valve disease, and large vegetations (>10 mm) reduces the composite of in-hospital death and embolic events from 50% to 23% (NNT = 4).
- •NOVA score, Used to stratify risk of IE in E. faecalis bacteremia. ≥4 points (≥2 positive cultures [5], unknown origin [4], prior valve disease [2], murmur [1]) warrants echocardiography (sensitivity 92%).
- •Culture-negative endocarditis, Accounts for 5-10% of cases. Most common causes: Bartonella spp., Coxiella burnetii, prior antibiotic exposure. Diagnose with serology (C. burnetii phase I IgG ≥1:800) and 16S rRNA PCR of valve tissue.
- •Right-sided IE, Most common in PWID. Presents with septic pulmonary emboli (cough, hemoptysis, pleuritic chest pain). Tricuspid valve most often affected. TTE is usually sufficient. Consider 2-week regimen for uncomplicated MSSA right-sided IE.
- •Endocarditis Team, Multidisciplinary team (cardiology, cardiac surgery, ID) reduces in-hospital mortality from 22.1% to 14.3% (NNT = 13) and shortens time to surgery.
Deep Dive — Evidence Details
Definition, Classification and Causative Organisms
- ▸Infective endocarditis is classified by temporal course (acute/subacute/chronic), mode of acquisition (community, healthcare-associated, injection drug use-related), and anatomic site (native valve, prosthetic valve, CIED), each with distinct microbiologic profiles that guide empiric therapy.
- ▸Staphylococcus aureus is the most common cause, responsible for 25-40% of cases, with MRSA comprising 30-50% of staphylococcal IE in healthcare settings.
- ▸Culture-negative endocarditis accounts for 10-30% of cases; Bartonella spp., Coxiella burnetii, and nutritionally variant streptococci are leading causes requiring serologic or molecular diagnosis.
Infective endocarditis (IE) is a life-threatening microbial infection of the endocardial surface, most commonly involving native or , the mural endocardium, or indwelling cardiac devices [17]A1c.
Also Called / Synonyms
- Bacterial endocarditis (BE)
- Subacute bacterial endocarditis (SBE), historical term for indolent presentations
- Acute bacterial endocarditis (ABE)
- Prosthetic valve endocarditis (PVE)
- Cardiac implantable electronic device-related endocarditis (CIED-IE)
- Fungal endocarditis (when caused by Candida spp., Aspergillus spp., etc.)
Classification Axes
IE is classified along three key axes that directly inform empiric therapy selection and urgency:
1. Temporal Course (Acute vs. Subacute vs. Chronic)
| Type | Onset | Typical Pathogens | Clinical Hallmark |
|---|---|---|---|
| Acute | Days to <2 weeks | Staphylococcus aureus , beta-hemolytic streptococci, Streptococcus pneumoniae | Rapidly progressive valve destruction, high fever, systemic toxicity; mortality up to 30% at 30 days [11]D5[15]D5 |
| Subacute | Weeks to months | Viridans group streptococci (VGS), Enterococcus spp., HACEK group | Indolent fever, night sweats, weight loss; vegetation formation with lower virulence [23]D5 |
| Chronic | Months | Bartonella spp., Coxiella burnetii, Tropheryma whipplei | Culture-negative, often with pre-existing valvular disease; may present with embolic phenomena [17]A1c[38]C4 |
2. Mode of Acquisition (Community- vs. Healthcare-Associated vs. Injection Drug Use-Related) This classification is critical because each category carries a distinct microbiologic profile that guides empiric [63]B2b.
- Community-acquired IE (CAIE): Approximately 38% of cases in contemporary series. Predominant pathogens are VGS, S. aureus, and Enterococcus faecalis [63]B2b[65]B2b.
- Healthcare-associated IE (HAIE): Accounts for 31% of cases. Divided into nosocomial (hospital-onset) and non-nosocomial (e.g., hemodialysis, recent IV therapy, institutionalization). S. aureus (including MRSA), coagulase-negative staphylococci (CoNS), and enterococci predominate [62]B2b[63]B2b.
- Injection drug use-related IE (IDUIE): Also 31% of cases in population-based cohorts. S. aureus is the dominant pathogen (>60%), with a high incidence of right-sided involvement (tricuspid valve) and or Candida spp. in some series [13]D5[63]B2b.
3. Anatomic Site (Valve Type)
| Type | Key Feature | Microbiology Emphasis |
|---|---|---|
| Native valve endocarditis (NVE) | Infects previously normal or damaged native valves | VGS, S. aureus, Enterococcus spp., HACEK [23]D5 |
| Prosthetic valve endocarditis (PVE) | Early PVE (≤12 months post-op): CoNS, S. aureus; Late PVE (>12 months): similar to NVE but with higher CoNS prevalence [21]B2b[41]B2b | |
| CIED-related endocarditis | Infection of pacing leads +/- valve involvement | CoNS (especially S. epidermidis), S. aureus; up to 10% are polymicrobial [6]D5 |
Causative Organisms
Gram-Positive Cocci cause >80% of all IE cases [23]D5.
- Staphylococcus aureus: The single most common cause in the developed world, responsible for 25-40% of cases. Methicillin-resistant S. aureus (MRSA) accounts for 30-50% of staphylococcal IE in healthcare-associated settings [11]D5[17]A1c. S. aureus possesses an array of surface adhesins (MSCRAMMs) and superantigens that enable rapid endothelial invasion and vegetation formation [14]D5[15]D5.
- Viridans Group Streptococci (VGS): Historically the most common cause; now 15-25% of cases. Species include Streptococcus sanguinis, S. mitis, S. oralis, and S. gordonii. High-level penicillin resistance (MIC ≥4 μg/mL) is emerging, warranting -based therapy [28]D5[32]C4.
- Enterococcus faecalis: Accounts for 10-15% of IE; commonly associated with healthcare exposure, urologic manipulation, and older age. Synergistic dual beta-lactam therapy ( plus ) is standard [1]A1a[19]B2b.
- Coagulase-Negative Staphylococci (CoNS): Staphylococcus epidermidis is the leading cause of early PVE and CIED-IE. Often methicillin-resistant, requiring vancomycin or [6]D5[41]B2b.
- Nutritionally Variant Streptococci (NVS): Abiotrophia defectiva and Granulicatella spp. cause 1-3% of IE; require media supplemented with pyridoxal for growth. Daptomycin nonsusceptibility is emerging [44]D5[48]D5.
HACEK Group (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, Kingella species) are fastidious gram-negative bacilli causing 5-10% of community-acquired IE, particularly in patients with prior dental disease. They produce beta-lactamase in up to 30%, making ceftriaxone the agent of choice [12]D5[17]A1c.
Gram-Negative Bacilli (Non-HACEK): Serratia marcescens, Pseudomonas aeruginosa, and Klebsiella spp. are increasing, especially among persons who inject drugs (PWID) and those with healthcare contact. Serratia spp. accounted for 43% of gram-negative IE cases in a recent cohort from 2010-2021, with a 42-day mortality of 21% [58]B2b.
Fungi: Candida spp. (primarily C. albicans and C. parapsilosis) cause 1-3% of IE, predominantly in patients with prosthetic valves, central venous catheters, or prior cardiac surgery. Mortality remains 36-40% despite combined antifungal and surgical therapy [4]B2b[22]B2b.
Culture-Negative Endocarditis (CNE): Accounts for 10-30% of IE [67]B2b. Causative agents include:
- Bartonella quintana and B. henselae: Leading causes of CNE globally; diagnosed by serology (≥1:800 IgG) or PCR of valve tissue [36]C4[38]C4[70]C4.
- Coxiella burnetii (Q fever): Considered in patients with exposure to livestock or unpasteurized dairy [17]A1c.
- Tropheryma whipplei: Rare cause of chronic, culture-negative IE with negative serology [17]A1c.
- Cutibacterium avidum: An underrecognized skin commensal causing prosthetic valve and device-related CNE [16]D5.
- Other fastidious organisms: Corynebacterium diphtheriae (causing IE with cutaneous in 17% of recent South African cases), Abiotrophia/Granulicatella (NVS), and Spiroplasma apis in immunocompromised patients [40]C4[44]D5[68]C4.
Clinical Significance
IE carries a 1-year mortality of approximately 30%, worse than many malignancies, and has not improved in the past three decades despite advances in diagnostics and surgery [23]D5[42]B2c. Prompt recognition of the causative organism and classification by temporal course, acquisition mode, and valve type is essential to guide effective empiric and definitive therapy.
Pearl: Staphylococcus aureus is now the dominant cause of infective endocarditis worldwide, driven by healthcare-associated and injection drug use-related cases; its ability to cause acute valve destruction demands early surgery consideration and antistaphylococcal coverage active against MRSA in high-risk settings [11]D5[17]A1c[63]B2b.
| Classification Axis | Category | Key Feature | Microbiology Emphasis |
|---|---|---|---|
| Temporal Course | Acute (days to <2 wks) | Rapid valve destruction, high fever | S. aureus, beta-hemolytic streptococci |
| Temporal Course | Subacute (wks to months) | Indolent fever, weight loss | Viridans group streptococci, Enterococcus spp., HACEK |
| Temporal Course | Chronic (months) | Insidious, culture-negative | Bartonella spp., Coxiella burnetii |
| Acquisition Mode | Community-acquired (CAIE) | No recent healthcare contact | Viridans group streptococci, S. aureus, Enterococcus |
| Acquisition Mode | Healthcare-associated (HAIE) | Hospitalization or IV therapy within 90 days | S. aureus (incl. MRSA), CoNS, Enterococcus |
| Acquisition Mode | Injection drug use-related (IDUIE) | Active IVDU | S. aureus (>60%), Pseudomonas, Candida |
| Valve Type | Native valve (NVE) | Infection of natural valve | Viridans streptococci, S. aureus |
| Valve Type | Prosthetic valve (PVE) | Early (≤12 mo): CoNS; Late: similar to NVE | CoNS (early), S. aureus, Enterococcus |
| Valve Type | CIED-related | Lead +/- valve infection | CoNS (esp. S. epidermidis), S. aureus |
Microbiology and Pathogenesis
- ▸Endothelial injury from turbulent flow or direct trauma initiates platelet-fibrin deposition, creating a scaffold for bacterial adherence.
- ▸S. aureus uses fibronectin-binding proteins and clumping factors to adhere to damaged endothelium, while its agr system and superantigens drive virulence and treatment failure.
- ▸Vegetation maturation involves biofilm-like growth and embolization, with host immune responses often ineffective.
Endothelial injury, platelet-fibrin deposition, and microbial adherence form the sequential triad that transforms a sterile thrombus into an infected vegetation [15]D5[77]B2b. This cascade begins when turbulent blood flow, from congenital valve disease, prosthetic material, or intracardiac devices, denudes the endothelium, exposing subendothelial collagen and fibronectin. In people who inject drugs (PWID), particulate matter directly traumatizes right-sided valves, creating a nidus for infection [13]D5[89]D5.
Endothelial Injury and the Nonbacterial Thrombotic Vegetation
Exposed subendothelial matrix triggers platelet adhesion and activation, depositing a sterile platelet-fibrin thrombus known as nonbacterial thrombotic endocarditis (NBTE) [77]B2b. This thrombus provides the essential scaffold for bacterial adherence. The process is amplified by turbulent flow, which perpetuates endothelial damage and platelet aggregation.
Microbial Adherence and Vegetation Maturation
Bacteria express surface adhesins that bind to matrix proteins within the NBTE. Staphylococcus aureus employs fibronectin-binding proteins (FnBPs) and clumping factors to anchor to fibronectin and fibrinogen, respectively [15]D5. Viridans group streptococci produce dextran and bind to platelet aggregates, while Streptococcus gallolyticus (formerly S. bovis) uses similar mechanisms and is strongly linked to [84]D5[90]D5. Enterococci and HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) also express adhesins that facilitate colonization [12]D5.
Once adherent, bacteria proliferate within the thrombus, forming dense microcolonies embedded in a biofilm-like matrix. The S. aureus accessory gene regulator (agr) system controls the switch from adhesion to toxin production; early agr activation correlates with treatment failure in experimental endocarditis [82]D5[86]D5. Superantigens, such as toxic shock syndrome toxin-1 (TSST-1) and enterotoxins, cause massive T-cell activation and cytokine release, contributing to sepsis and immune dysregulation [14]D5.
Virulence Factors and Host Interaction
S. aureus is particularly virulent due to its arsenal of adhesins, toxins, and the ability to invade and persist within endothelial cells [15]D5. The organism can also form small-colony variants that resist and evade host defenses. In contrast, viridans group streptococci rely on dextran production and plasminogen binding, which may destabilize vegetations and promote embolization [84]D5. Host immune responses, neutrophils, complement, and antibodies, are often ineffective within the protected biofilm, leading to persistent infection. Immune complexes deposit in glomeruli (glomerulonephritis) and skin (Osler nodes) [91]D5.
Special Populations
In PWID, repeated injections introduce skin flora (S. aureus, streptococci) and contaminants, with higher rates of Gram-negative bacilli (e.g., , Serratia marcescens) [85]B2b[92]D5. Prosthetic valve endocarditis involves biofilm formation on synthetic material, with S. aureus and coagulase-negative staphylococci predominating [71]B2b. Unusual organisms, such as Cutibacterium acnes, Coxiella burnetii, and fungi, have distinct pathogenic mechanisms and often require specialized diagnostics [95]B2b.
Pearl: The pathogenesis of infective endocarditis is a stepwise process of endothelial injury, sterile thrombus formation, and microbial adherence, with S. aureus virulence factors, particularly FnBPs and the agr system, driving the most aggressive disease and treatment failure [15]D5[82]D5[86]D5.
Epidemiology, Transmission and Risk Factors
- ▸IE incidence is increasing in high-income countries due to injection drug use, device implants, and an aging population.
- ▸Prosthetic valves, prior IE, and injection drug use are the strongest risk factors, with hydromorphone injection conferring a 2.3-fold higher risk.
- ▸Rheumatic heart disease remains the predominant substrate for IE in low- and middle-income countries.
The global incidence of infective endocarditis (IE) ranges from 1 to 2 per 100,000 person-years in high-income countries to over 10 per 100,000 in regions with high (RHD) prevalence [116]D5[120]D5. In the United States, age-adjusted incidence is approximately 15 per 100,000, with an estimated 40,000 to 50,000 cases annually [120]D5. Median age at diagnosis has risen to 67-75 years, and men are affected twice as often as women [23]D5[148]B2c. IE incidence has increased over the past two decades, driven by the opioid epidemic, expanding use of implantable cardiac devices and transcatheter ( ), and an aging population with healthcare-associated exposures [42]B2c[118]B2a. IDU-associated IE increased disproportionately, with rural areas experiencing a 13-fold rise from 0.28 to 3.86 per 100,000 rural residents between 2003 and 2016 [149]B2c.
Risk factors span patient-related, cardiac, and healthcare-associated categories (Table 1). The strongest predisposing conditions are (OR 50-100), prior IE (OR 10-20), and injection drug use (OR 10-30) [23]D5[116]D5. Among people who inject drugs, injection carries a particularly high risk (HR 2.31, 95% CI 1.43-3.73) [105]B2b[124]B2b. Healthcare-associated IE accounts for 25-35% of cases in high-income countries, often related to intravascular catheters, hemodialysis, or recent cardiac surgery [63]B2b[120]D5. Cardiac implantable electronic devices (CIEDs) are implicated in 10-20% of IE cases, with an incidence of 1-2% per year after implantation [133]B2b. TAVR-associated IE has a cumulative incidence of 1.1% at 1 year and 2.5% at 2 years, with Enterococcus species disproportionately represented [73]B2b[134]B2b.
| Risk Factor | Odds Ratio / Relative Risk | Evidence Level |
|---|---|---|
| Prosthetic heart valve | OR 50-100 | 2b [23]D5[116]D5 |
| Prior infective endocarditis | OR 10-20 | 2b [23]D5 |
| Injection drug use | OR 10-30 | 2b [13]D5[100]A1a |
| Hydromorphone injection (vs other opioids) | HR 2.31 (95% CI 1.43-3.73) | 2b [105]B2b |
| Congenital heart disease | OR 5-10 | 2b [23]D5 |
| Rheumatic heart disease | OR 5-10 (in endemic areas) | 2b [132]B2b |
| Degenerative valve disease | OR 2-5 | 2b [23]D5 |
| Hemodialysis | OR 5-10 | 2b [120]D5 |
| Diabetes mellitus | OR 1.5-2 | 2b [23]D5 |
| Cardiac implantable electronic device | OR 5-10 | 2b [133]B2b |
| TAVR (vs SAVR) | HR 1.5-2 for early IE | 2b [21]B2b[73]B2b |
| Recent dental procedure (without prophylaxis) | OR 1.5-3 | 2b [103]B2b[123]B2c |
Seasonal variation has not been consistently demonstrated [148]B2c. In pregnancy, IE is rare (0.006% of deliveries) but carries high maternal and fetal mortality [59]B2b[110]B2c. Pediatric IE is uncommon, with Kingella kingae emerging as a leading pathogen in children under 3 years with congenital heart disease [31]B3b[128]B2b. In low- and middle-income countries, RHD remains the predominant substrate, and zoonotic pathogens (Bartonella, Coxiella burnetii) are important causes of culture-negative IE [38]C4[67]B2b[150]B2b.
Pearl: The of IE has shifted dramatically: an aging population with prosthetic devices and healthcare contact, combined with the opioid epidemic, now defines the contemporary risk profile, while RHD remains the dominant substrate in resource-limited settings [23]D5[116]D5[120]D5.
Clinical Presentation
- ▸Clinical presentation spans acute (days) to subacute (weeks to months), determined by organism virulence and host factors.
- ▸Fever and a new or changing heart murmur are the classic findings, but fever may be absent in elderly or immunocompromised patients.
- ▸Neurological symptoms (stroke, TIA, mycotic aneurysm) may be the first manifestation; cerebral imaging detects emboli in 44% of patients, even without symptoms.
The clinical presentation spans a spectrum from acute, fulminant sepsis to an indolent, low-grade febrile illness, determined largely by the causative organism and host factors [23]D5[116]D5. The incubation period is typically days to weeks; acute endocarditis (most often due to Staphylococcus aureus ) can declare itself within days, whereas subacute forms (viridans group streptococci, enterococci, HACEK organisms) evolve over weeks to months [23]D5[116]D5.
Presenting Symptoms
Fever is the most consistent symptom, present in >90% of patients, though it may be absent in the elderly, the immunocompromised, or those with prior antibiotic exposure [23]D5[116]D5. Chills, night sweats, anorexia, and weight loss are common in subacute disease. Acute IE presents with high fever, rigors, and rapid hemodynamic deterioration. Dyspnea, chest pain, and cough may signal heart failure or pulmonary emboli (right-sided IE). Musculoskeletal complaints, arthralgias, myalgias, back pain, occur in up to 25% of patients and can dominate the early picture [23]D5.
Physical Examination Findings
A cardiac murmur is heard in approximately 85% of patients with left-sided IE; a new or changing murmur is a classic finding [23]D5[116]D5. Right-sided IE (tricuspid or pulmonic) may lack a murmur or produce a soft, blowing systolic murmur that increases with inspiration. Peripheral stigmata, though less common in modern practice, remain highly specific:
- Osler nodes: painful, erythematous nodules on the finger/toe pads (immune complex deposition).
- Janeway lesions: painless, hemorrhagic macules on palms/soles (septic emboli).
- Splinter hemorrhages: linear, dark streaks under the nails.
- Roth spots: retinal hemorrhages with pale centers, seen on fundoscopy in 5% of cases [151]B2b.
- Conjunctival petechiae: small, red spots on the conjunctivae. Fundoscopy has low diagnostic yield; Roth spots and retinal emboli are found in only 5% of patients and do not alter Duke criteria classification [151]B2b.
Neurological and Embolic Manifestations
Cerebral embolic events occur in 20-40% of patients and may be the presenting feature [153]B3b. Stroke (ischemic or hemorrhagic), transient ischemic attack, , meningitis, or can occur. Cerebral imaging reveals emboli in 44% of patients with suspected IE, even in the absence of neurological symptoms, and can upgrade the diagnostic classification from possible to definite IE [153]B3b. Septic emboli to the spleen, kidney, or extremities cause flank pain, hematuria, or limb ischemia.
Phenotypic Variants
| Variant | Key Features | Frequency |
|---|---|---|
| Acute IE | High fever, rapid valve destruction, metastatic abscesses; S. aureus most common | ~30% of cases |
| Subacute IE | Low-grade fever, weight loss, insidious course; viridans streptococci, enterococci | ~50% of cases |
| Right-sided IE | Pulmonary emboli, septic pulmonary infarcts, often no murmur; PWID, CIED | ~10% of cases |
| Prosthetic valve IE | Early (<1 year): S. aureus, coagulase-negative staphylococci; late (>1 year): similar to native | ~20% of cases |
| Fungal IE | Large vegetations, high embolic rate, poor prognosis; Candida, Aspergillus | 1-3% of cases [109]D5 |
| Culture-negative IE | Bartonella, Coxiella burnetii, Tropheryma whipplei; often afebrile, oligosymptomatic | 5-10% of cases [38]C4[169]D5 |
Red Flags
- New or changing heart murmur in a febrile patient, IE until proven otherwise.
- Persistent bacteremia (especially S. aureus) despite appropriate .
- or new conduction abnormality (abscess formation).
- Neurological symptoms (stroke, seizure, headache) in a patient with risk factors.
- Septic emboli to skin, spleen, or extremities.
Atypical Presentations
Elderly patients may present with confusion, anorexia, or falls without fever [23]D5. Immunocompromised hosts (e.g., solid organ transplant, HIV) may have muted inflammatory responses. Culture-negative IE due to Bartonella quintana or Coxiella burnetii often presents as afebrile, oligosymptomatic endocarditis with high IgG titers [38]C4[150]B2b. Whipple's endocarditis (Tropheryma whipplei) can mimic degenerative valve disease and may be unmasked by biologic response modifiers [169]D5.
Pearl: The combination of fever and a new or changing heart murmur remains the classic presentation, but the absence of fever does not exclude IE, especially in elderly or immunocompromised patients; a high index of suspicion is required when peripheral stigmata, embolic phenomena, or persistent bacteremia are present [23]D5[116]D5.
Diagnosis and Workup
- ▸Obtain at least three blood culture sets before antibiotics; persistent bacteremia with a typical pathogen (S. aureus, viridans streptococci, enterococci) is a major Duke criterion.
- ▸Transesophageal echocardiography (TEE) is the test of choice when TTE is negative or prosthetic material is present, with sensitivity >90% for native valve vegetations.
- ▸In culture-negative endocarditis (5-10%), serology for Coxiella burnetii and Bartonella spp., plus 16S PCR of valvular tissue, should be pursued; plasma mcfDNA sequencing is a newer adjunct.
The diagnosis of infective endocarditis rests on a structured synthesis of clinical, microbiologic, and imaging findings, formalized in the modified Duke criteria (sensitivity ~80% for native valve disease, lower for prosthetic material) [101]B2a. Because 1-year mortality approaches 30%, the diagnostic process must be rapid, systematic, and multidisciplinary [23]D5. No single test is sufficient; the gold standard is a definite diagnosis by the modified Duke criteria, integrating two major criteria (persistent bacteremia and echocardiographic vegetation) or one major plus three minor criteria, as adjudicated by an Endocarditis Team [20]B2b[116]D5.
Blood Cultures, The Critical First Step
Obtain at least three sets of blood cultures (each set = one aerobic + one anaerobic bottle) from separate venipuncture sites before starting , ideally over 30-60 minutes [20]B2b[23]D5. A single-sampling strategy (all bottles drawn simultaneously) has lower sensitivity than the conventional multisampling strategy for detecting the major microbiologic criterion of the 2015 ESC guidelines; the conventional strategy remains standard [20]B2b. The single most important microbiologic finding is persistent bacteremia: two or more positive cultures drawn >12 hours apart, or three or more of four positive cultures with the first and last drawn ≥1 hour apart [23]D5[116]D5. In Staphylococcus aureus bacteremia, a short time to positivity (TTP), typically ≤12-14 hours, increases the likelihood of IE and should lower the threshold for echocardiography [3]B2b[166]B3b.
The Modified Duke Criteria
The modified Duke criteria assign patients to definite, possible, or rejected IE categories. The major criteria are: (1) persistent bacteremia with a typical IE pathogen (viridans group streptococci, S. aureus, or enterococci) from ≥2 blood cultures, or a single positive culture for Coxiella burnetii or anti-phase I IgG ≥1:800; and (2) echocardiographic evidence of vegetation, abscess, or new partial dehiscence of a prosthetic valve [101]B2a[116]D5. Minor criteria include predisposing heart condition or injection drug use, fever ≥38°C, vascular phenomena (arterial emboli, septic pulmonary infarcts, ), immunologic phenomena (glomerulonephritis, Osler nodes, Roth spots), and microbiologic evidence not meeting major criteria [23]D5[116]D5. In patients with suspected IE and negative blood cultures, serology for C. burnetii and Bartonella species, plus polymerase chain reaction (PCR) of vegetations or embolic material, can upgrade the diagnosis [38]C4[183]C4.
Echocardiography, The Essential Imaging Modality
Transthoracic echocardiography (TTE) should be performed first in all patients with suspected IE [23]D5[116]D5. TTE has a sensitivity of 50-65% for native valve vegetations but only 25-35% for prosthetic valve endocarditis (PVE) [116]D5. Transesophageal echocardiography (TEE) is the test of choice when clinical suspicion persists despite a negative TTE, when prosthetic material is present, or when TTE is nondiagnostic [9]B2b[116]D5. TEE increases sensitivity for native valve disease to 90-95% and for PVE to 85-90%, and it is superior for detecting perivalvular abscesses, leaflet perforations, and prosthetic dehiscence [116]D5[206]C4. Intracardiac echocardiography (ICE) is a newer, catheter-based modality that provides high-resolution real-time imaging, particularly useful for device-related IE; its diagnostic performance relative to TEE is under investigation [152]A1c.
Advanced Imaging in Difficult Cases
When echocardiography is inconclusive, especially in PVE or cardiac implantable electronic device infections, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has emerged as a valuable adjunct [101]B2a[153]B3b. A systematic review reported that FDG PET/CT identifies abnormal periprosthetic uptake with sensitivity 70-85% and specificity 80-90% for PVE [101]B2a. ECG-gated multidetector CT angiography (MDCTA) provides complementary anatomic detail, identifying perivalvular abscesses, pseudoaneurysms, and fistulae with high accuracy [101]B2a. Cerebral imaging (CT or MRI) is recommended in all patients with suspected IE or neurologic symptoms, as cerebral embolic events are found in 44% of patients and can upgrade the Duke classification from possible to definite [153]B3b.
Culture-Negative Endocarditis
Blood cultures remain negative in 5-10% of cases, often due to prior antibiotic administration or fastidious organisms [109]D5[178]B3b. When cultures are negative, a structured workup includes serology for C. burnetii (phase I IgG ≥1:800 is diagnostic), Bartonella species, and Brucella species, and broad-range 16S rRNA PCR of excised valvular tissue or embolic material [36]C4[38]C4[178]B3b[183]C4. Plasma microbial cell-free DNA (mcfDNA) sequencing (Karius test) can identify pathogens in culture-negative cases, with reported diagnostic yields of 30-50% when conventional testing is negative, though its sensitivity is lower for fungi and some intracellular bacteria [61]B2b[180]B3b. Fluorescence in situ hybridization (FISH) combined with 16S PCR (FISHseq) applied to resected valves further improves detection, particularly for fastidious organisms like Cutibacterium acnes and Tropheryma whipplei [177]B3b[207]C4.
Diagnostic Algorithm
- Clinical suspicion, fever + murmur + vascular/immunologic phenomena + risk factors (prosthetic valve, prior IE, injection drug use, congenital heart disease).
- Obtain ≥3 blood culture sets from separate sites before antibiotics; start empiric antibiotics only after cultures are drawn [20]B2b[198]B3b.
- Perform TTE immediately. If TTE is positive for vegetation/abscess → proceed to TEE for detailed anatomic assessment [116]D5.
- TEE is mandatory if prosthetic material is present, TTE is negative or nondiagnostic, or S. aureus bacteremia is documented [23]D5[160]D5.
- Apply modified Duke criteria (ESC 2015 or Duke-ISCVID 2023) [101]B2a[154]B2b.
- If cultures negative at 48-72 hours, test for C. burnetii IgG, Bartonella IgG, Brucella serology; consider mcfDNA sequencing or valve PCR if surgery is performed [38]C4[61]B2b[180]B3b[183]C4.
- If echocardiography is equivocal, obtain FDG PET/CT (for PVE) or cardiac CT angiography [101]B2a[153]B3b.
- Cerebral imaging (CT/MRI) is indicated in all patients with neurologic symptoms or high-risk features (e.g., S. aureus IE) [153]B3b.
- Endocarditis Team (cardiologist, cardiac surgeon, infectious disease specialist) adjudicates all cases and directs [116]D5.
Differential Diagnosis
The differential includes nonbacterial thrombotic endocarditis (marantic endocarditis, associated with malignancy, SLE, antiphospholipid syndrome), rheumatic fever (migratory arthritis, chorea, elevated ASO titers), (can produce emboli and obstructive symptoms but negative blood cultures and no fever), acute pericarditis, systemic vasculitis ( , ANCA-associated vasculitis), and septic emboli from an extracardiac source (e.g., suppurative thrombophlebitis). Cerebral embolic events in the absence of IE should prompt evaluation for , carotid artery disease, or hypercoagulable states [153]B3b.
Pearl: The diagnosis of infective endocarditis requires integration of persistent bacteremia (a major criterion) with echocardiographic or advanced imaging evidence of vegetation or perivalvular infection; the Endocarditis Team is essential for accurate classification, especially in culture-negative or device-related cases where adjunctive serology, PCR, and FDG PET/CT substantially improve diagnostic yield [23]D5[101]B2a[116]D5[153]B3b[180]B3b.
| Disease Category | Presentation Stage | Key Features |
|---|---|---|
| Acute IE | Days | High fever, sepsis, rapidly destructive valve lesions, embolic events; often S. aureus [23]D5[116]D5. |
| Subacute IE | Weeks to months | Low-grade fever, night sweats, weight loss; often viridans group streptococci or enterococci [23]D5. |
| Prosthetic Valve IE | Variable | Fever (often absent), valve dehiscence, perivalvular abscess; higher risk of culture negativity [101]B2a[177]B3b. |
| Device-Related IE | Weeks to months | Fever, pocket infection, lead vegetation; common pathogens: S. aureus, CoNS, Cutibacterium acnes [6]D5[102]A1c. |
| Culture-Negative IE | Subacute/chronic | Negative blood cultures; must consider prior antibiotics, Q fever, Bartonella, HACEK, fungi [38]C4[109]D5[178]B3b[183]C4. |
Severity Assessment and Risk Stratification
- ▸The NOVA score (≥4 points) stratifies *Enterococcus faecalis* bacteremia patients for IE risk, guiding echocardiography with 92% sensitivity [217].
- ▸Cardiogenic shock (5% of IE) carries 52.5% in-hospital mortality; early surgery reduces mortality with NNT = 6 [214].
- ▸Multidisciplinary endocarditis teams reduce in-hospital mortality from 22.1% to 14.3% (NNT = 13) [227].
Risk Scores for Pathogen-Specific Stratification
For patients with Enterococcus faecalis bacteremia, the NOVA score stratifies the risk of concomitant infective endocarditis (IE). A score ≥4 points (derived from ≥2 positive blood cultures [5 points], unknown origin [4 points], prior valve disease [2 points], and heart murmur [1 point]) identifies patients warranting echocardiography; in the validation cohort, a NOVA score ≥4 had a sensitivity of 92% and specificity of 62% for IE [217]B2b. For Staphylococcus aureus bacteremia, a single positive blood culture bottle still represents clinically significant IE in 89.8% of cases, mandating full evaluation [96]B2b.
Clinical Risk Factors for Mortality
Several validated risk factors guide intensity of therapy and site-of-care decisions. (CS) occurs in 5% of IE patients and carries an in-hospital mortality of 52.5% (vs 39.1% for without CS); early surgery in CS reduces mortality (HR 0.67, 95% CI 0.52-0.85; NNT = 6 to prevent one death) [214]B2b. Septic shock (SS) affects 12.3% of patients, with in-hospital mortality of 62.3% (vs 16.3% for no shock); independent predictors of SS include diabetes, chronic renal disease, and S. aureus etiology [218]B2b. In patients aged ≥80 years, the MoISE study identified Charlson comorbidity index ≥3 and prosthetic valve IE as independent predictors of 1-year mortality, with surgery offered to only 36% of those with a surgical indication [212]B2b. A nomogram for 30-day mortality (c-statistic 0.82) incorporates age, heart failure, cerebral embolism, and S. aureus infection [222]B3b. Long-term, IE confers a 1.47-fold increased risk of hemorrhagic stroke (95% CI 1.2-1.8) persisting beyond 1 year [210]B2b. Socioeconomic disparities also affect outcomes: low educational level is associated with a 1.3-fold higher 5-year mortality (95% CI 1.1-1.6) [223]B2b.
Role of the Endocarditis Team and Imaging in Risk Stratification
Establishment of a multidisciplinary Endocarditis Team reduces in-hospital mortality from 22.1% to 14.3% (HR 0.65, 95% CI 0.43-0.98; NNT = 13) and shortens time to surgery [227]B2b. Systematic thoracoabdominal-pelvic CT (TAP-CT) modifies the Duke classification in 18% of patients and alters surgical planning in 12% [213]B2b. Absence of echocardiographic signs (vegetation, abscess, fistula) occurs in 15.1% of TAVI-IE patients and is associated with lower in-hospital mortality (OR 0.42, 95% CI 0.22-0.80) [156]B3b. Perivalvular extension (abscess, pseudoaneurysm, fistula) complicates 18.1% of TAVI-IE and independently predicts 1-year mortality (HR 1.8, 95% CI 1.3-2.5) [211]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine TAP-CT in all IE? | ESC guidelines recommend systematic TAP-CT to detect extracardiac complications [213]B2b. | AHA/ACC guidelines reserve CT for selected cases with suspected embolic events. | Moderate | Centers adopting routine TAP-CT report higher rates of Duke reclassification and surgical plan changes, but no randomized trial confirms survival benefit. |
| Role of valve culture in prognosis? | Positive valve culture at surgery predicts higher in-hospital mortality (OR 2.1, 95% CI 1.3-3.4) [216]B3b. | Valve culture results rarely alter postoperative antibiotic duration in contemporary practice. | Low | Positive valve culture may identify patients needing prolonged therapy, but data are observational. |
Pearl: Early risk stratification using the NOVA score for E. faecalis bacteremia, recognition of cardiogenic or septic shock, and prompt referral to an endocarditis team reduce mortality by identifying patients who benefit from intensive care and early surgery [214]B2b[217]B2b[227]B2b.
| Tool / Factor | Population | Threshold / Finding | Outcome | Reference |
|---|---|---|---|---|
| NOVA score | E. faecalis bacteremia | ≥4 points | Sensitivity 92% for IE | [217]B2b |
| Cardiogenic shock | All IE | Present | In-hospital mortality 52.5%; NNT 6 for surgery | [214]B2b |
| Septic shock | All IE | Present | In-hospital mortality 62.3% | [218]B2b |
| Charlson comorbidity index | Age ≥80 years | ≥3 | 1-year mortality HR 2.1 | [212]B2b |
| Absent echo signs | TAVI-IE | No vegetation/abscess/fistula | Lower in-hospital mortality (OR 0.42) | [156]B3b |
| Perivalvular extension | TAVI-IE | Abscess/pseudoaneurysm/fistula | 1-year mortality HR 1.8 | [211]B2b |
| Endocarditis Team | All IE | Multidisciplinary care | In-hospital mortality reduction from 22.1% to 14.3% | [227]B2b |
Empiric and Acute Management
- ▸Empiric therapy must be initiated rapidly (within 1-2 hours in unstable patients) after blood cultures; the choice depends on community-acquired vs. healthcare-associated presentation and the presence of injection drug use.
- ▸Ampicillin plus ceftriaxone is the preferred dual β-lactam regimen for Enterococcus faecalis IE, avoiding the nephrotoxicity of aminoglycosides.
- ▸Early surgery (within 48 hours) in patients with left-sided IE, severe valve disease, and large vegetations reduces the composite of death and embolic events (NNT = 4).
- ▸Oral step-down therapy after 10 days of IV antibiotics is a safe option in hemodynamically stable patients without uncontrolled heart failure or perivalvular abscess.
Step 1: Initial Assessment and Severity Classification
Classify severity at presentation based on hemodynamic stability, the presence of acute valve regurgitation, and embolic risk. Patients with septic shock, (new York Heart Association class III/IV), or large vegetations (>10 mm) with embolic events require immediate intensive care unit (ICU) admission and urgent cardiothoracic surgery consultation [104]A1b (1b). Stable patients without these features can be managed on a ward with continuous telemetry monitoring. The 2023 Duke-ISCVID criteria should be applied to establish a diagnostic probability, but empiric therapy must not be delayed while awaiting culture results, especially in the presence of sepsis [17]A1c (1c). Obtain at least three sets of blood cultures from separate venipuncture sites before starting , ideally within 20 minutes if the patient is stable; however, administration should not be deferred for more than 1-2 hours in hemodynamically unstable patients [198]B3b (3b).
Step 2: Empiric Antibiotic Regimen
Select empiric antibiotics based on the most likely pathogen given the clinical scenario. For community-acquired native valve endocarditis in a patient without injection drug use, the most common organisms are viridans group streptococci and enterococci. Initiate 2 g IV every 4 hours plus 2 g IV every 12 hours; this dual β-lactam regimen covers streptococci and provides synergistic activity against Enterococcus faecalis [19]B2b (2b), [51]B2b (2b). For healthcare-associated or prosthetic valve endocarditis, or in persons who inject drugs (PWID), Staphylococcus aureus (including MRSA) predominates [13]D5 (5). Start 15-20 mg/kg IV every 8-12 hours (target trough 15-20 µg/mL) plus 2 g IV every 8 hours to cover MRSA and Gram-negative bacilli [27]D5 (5), [58]B2b (2b). In patients with (non-anaphylactic), cefazolin can replace ampicillin for streptococcal coverage, but for MRSA, vancomycin remains first-line [235]B2b (2b). For culture-negative endocarditis (e.g., after prior antibiotics, or suspected Bartonella, Coxiella burnetii), add 100 mg IV every 12 hours plus hydroxychloroquine for chronic Q fever, or follow specific PCR-directed therapy [17]A1c (1c). A summary of initial empiric choices is provided in Table 1.
Table 1. Empiric Antibiotic Regimens by Clinical Scenario
| Clinical Scenario | Empiric Regimen | Rationale | Key Evidence |
|---|---|---|---|
| Community-acquired, native valve, no IDU | Ampicillin 2 g IV q4h + Ceftriaxone 2 g IV q12h | Covers streptococci, E. faecalis | [19]B2b (2b), [51]B2b (2b) |
| Healthcare-associated / prosthetic valve / IDU | Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20) + Cefepime 2 g IV q8h | Covers MRSA, Gram-negatives | [27]D5 (5), [58]B2b (2b) |
| Culture-negative / suspected Bartonella / Q fever | Add Doxycycline 100 mg IV q12h ± Hydroxychloroquine | Directed at fastidious intracellular organisms | [17]A1c (1c) |
| Penicillin allergy (non-anaphylactic) | Consider Cefazolin 2 g IV q8h (for strep) + Vancomycin (for MRSA) | Alternative β-lactam for strep coverage | [235]B2b (2b) |
Step 3: Source Control - Surgical Indications
Early surgical consultation is mandatory for any patient with IE and a surgical indication. The randomized EASE trial demonstrated that early surgery (within 48 hours) in patients with left-sided IE, severe valve disease, and large vegetations (>10 mm) reduced the composite endpoint of in-hospital death or embolic events from 50% to 23% (absolute risk reduction 27%, NNT = 4) compared with conventional care [104]A1b (1b). Indications for urgent/emergent surgery include: (1) acute severe aortic or causing heart failure, (2) persistent bacteremia despite 5-7 days of appropriate antibiotics, (3) recurrent emboli despite therapy, (4) large vegetation >10 mm with prior embolic event, (5) prosthetic valve dehiscence or obstruction, and (6) fungal IE [109]D5 (5), [120]D5 (5). For septic emboli to the brain, surgery should be delayed at least 4 weeks after the neurological event unless the abscess requires immediate drainage [252]C4 (4).
Step 4: Supportive Care and Monitoring
Do NOT use aminoglycosides routinely as adjunctive therapy for E. faecalis IE. The meta-analysis by Prosty et al. (PMID 39041860) found no difference in clinical cure with gentamicin-based regimens versus ceftriaxone-based regimens, but gentamicin significantly increased nephrotoxicity (RR 2.1, 95% CI 1.3-3.4) [1]A1a (1a). For MRSA IE, 8-10 mg/kg IV every 24 hours (not 6 mg/kg) is recommended because the higher dose improves the area under the curve to MIC ratio, reducing the risk of treatment-emergent resistance and CPK elevation [9]B2b (2b). Monitor CPK weekly; discontinue daptomycin if CPK rises >5× the upper limit of normal with symptoms or >10× without symptoms [9]B2b. Obtain a transesophageal echocardiogram in all patients with S. aureus bacteremia (even without clinical signs of IE) to rule out valvular vegetations, as unrecognized IE drives therapeutic failure [160]D5 (5). Daily blood cultures should be drawn until they clear; persistent positivity after 48-72 hours of targeted therapy is an independent predictor of mortality and mandates a search for an undrained focus or reconsideration of surgical intervention [27]D5 (5).
Step 5: Transition to Oral Therapy and Outpatient Parenteral Antibiotic Therapy (OPAT)
The POET trial showed that after an initial 10-day course of IV antibiotics, switching to oral therapy (e.g., 1 g PO three times daily, or 600 mg PO twice daily for MRSA) was noninferior to continued IV therapy in patients with left-sided IE who were clinically stable and had no uncontrolled heart failure, no perivalvular abscess, and no prosthetic valve dehiscence [5]A1b (1b). The subsequent ENDO-ORAL observational study confirmed this strategy in real-world practice, including patients who were POET-ineligible (e.g., those with prosthetic valves or large vegetations), with 90-day clinical success rates >90% [231]B2b (2b). Eligible patients for oral step-down must meet the following criteria: (1) afebrile for ≥24 hours, (2) hemodynamically stable, (3) negative blood cultures for ≥48 hours, (4) no undrained abscess, (5) intact tract, (6) available oral regimen with ≥80% bioavailability. For patients who do not meet these criteria, outpatient parenteral antibiotic therapy (OPAT) is an alternative. The OPAT-GAMES criteria safely identify candidates: no cirrhosis, no severe central nervous system emboli, and a stable social situation [249]B2b (2b). Administer ampicillin-ceftriaxone via elastomeric pump (41°C stable for 24 hours) or a peripherally inserted central catheter [241]D5 (5). Dalbavancin, a long-acting lipoglycopeptide, can be administered as consolidation therapy once or twice weekly in patients with poor venous access, but evidence for its routine use is limited to case series with 6 of 7 cures reported in enterococcal IE [234]C4 (4).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Routine addition of gentamicin to ampicillin for E. faecalis IE | IDSA/EU guidelines (historical) : Adjunctive gentamicin for 2 weeks is acceptable [8]A1a (1a) | Prosty et al. meta-analysis 2024: No benefit, increased nephrotoxicity (RR 2.1); avoid gentamicin [1]A1a (1a) | Strong (newer high-level evidence contradicts older guideline recommendations) | Most centers have abandoned routine gentamicin; ampicillin + ceftriaxone is now first-line |
| Use of oral step-down therapy in POET-ineligible patients | ESC 2023 guidelines: Reserve oral step-down only for POET-eligible patients [5]A1b (1b) | ENDO-ORAL study 2026: Oral step-down was effective (90% clinical success) even in POET-ineligible subgroups [231]B2b (2b) | Moderate (observational data challenge guideline restriction) | Shared decision-making with the patient is appropriate; consider oral step-down in stable patients regardless of strict POET criteria |
Pearl: Start empiric ampicillin + ceftriaxone for community-acquired IE and vancomycin + cefepime for healthcare-associated IE; never delay antibiotics for blood culture results in unstable patients; and consider early oral step-down after 10 days in stable patients, as the POET trial demonstrated noninferiority with a 90-day clinical success rate of 90.9% versus 89.9% [5]A1b (1b).
| Clinical Scenario | Empiric Regimen | Rationale | Key Evidence |
|---|---|---|---|
| Community-acquired, native valve, no IDU | Ampicillin 2 g IV q4h + Ceftriaxone 2 g IV q12h | Covers streptococci, E. faecalis | [19]B2b (2b), [51]B2b (2b) |
| Healthcare-associated / prosthetic valve / IDU | Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20) + Cefepime 2 g IV q8h | Covers MRSA, Gram-negatives | [27]D5 (5), [58]B2b (2b) |
| Culture-negative / suspected Bartonella / Q fever | Add Doxycycline 100 mg IV q12h ± Hydroxychloroquine | Directed at fastidious intracellular organisms | [17]A1c (1c) |
| Penicillin allergy (non-anaphylactic) | Consider Cefazolin 2 g IV q8h (for strep) + Vancomycin (for MRSA) | Alternative β-lactam for strep coverage | [235]B2b (2b) |
Definitive Therapy, Duration and De-escalation
- ▸Ampicillin plus ceftriaxone is the preferred regimen for Enterococcus faecalis IE, with equivalent efficacy and significantly less nephrotoxicity than ampicillin plus gentamicin.
- ▸Oral step-down therapy after ≥10 days of IV therapy is noninferior to continued IV therapy for left-sided IE in stable patients (POET trial).
- ▸Duration is 4 weeks for native valve IE and 6 weeks for prosthetic valve IE; shorter courses (2 weeks) are reserved for uncomplicated right-sided IE.
Once the causative organism and its antimicrobial susceptibilities are confirmed, therapy shifts from empiric coverage to a targeted regimen selected for bactericidal activity, biofilm penetration, and synergy where required [120]D5. The choice of agent, dose, and duration depends on the pathogen, valve type (native vs prosthetic), and presence of complications.
Definitive Regimens by Pathogen
The table below summarizes first-line definitive regimens for the most common IE pathogens. Doses assume normal renal and hepatic function unless otherwise noted.
| Pathogen | Regimen | Dose | Duration | Key Evidence |
|---|---|---|---|---|
| Penicillin-susceptible viridans group streptococci (MIC ≤0.12 μg/mL) | Penicillin G or Ceftriaxone | 12-18 million U/day IV continuous or 4-6 divided doses; Ceftriaxone 2 g IV q24h | 4 weeks (native), 6 weeks (prosthetic) | [28]D5 |
| Penicillin-resistant viridans group streptococci (MIC >0.5 μg/mL) | or Ceftriaxone + Gentamicin | Vancomycin 15-20 mg/kg IV q12h (trough 15-20 μg/mL); Ceftriaxone 2 g IV q12h + Gentamicin 3 mg/kg IV q24h | 4-6 weeks | [32]C4 |
| Enterococcus faecalis | + Ceftriaxone (preferred) | Ampicillin 2 g IV q4h; Ceftriaxone 2 g IV q12h | 6 weeks | [19]B2b[261]B2b |
| MSSA | Cefazolin or Cloxacillin | Cefazolin 2 g IV q8h; Cloxacillin 12 g/day continuous infusion | 4-6 weeks | [47]C4[257]B2b |
| MRSA | Vancomycin or | Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20 μg/mL); Daptomycin 8-10 mg/kg IV q24h | 4-6 weeks | [160]D5[27]D5 |
| HACEK group | Ceftriaxone | 2 g IV q24h | 4 weeks | [120]D5 |
| Candida spp. | or Liposomal amphotericin B | 70 mg load then 50 mg IV q24h; L-AmB 3-5 mg/kg IV q24h | ≥6 weeks + valve replacement | [4]B2b[22]B2b[109]D5 |
For E. faecalis IE, ampicillin plus ceftriaxone is now the regimen of choice because it achieves equivalent cure rates (90-day mortality 20% vs 22% with ampicillin-gentamicin; HR 0.89, 95% CI 0.54-1.46) with significantly less nephrotoxicity (6% vs 24%; NNT = 6 to prevent one renal adverse event) [19]B2b[261]B2b. Gentamicin should be avoided when alternative synergy partners are available [1]A1a.
For MRSA, daptomycin at 8-10 mg/kg/day is preferred over vancomycin when the MIC is ≥1.5 μg/mL or when vancomycin fails [27]D5. High-dose daptomycin (10 mg/kg) achieves better PK/PD target attainment (AUC/MIC ratio >666) but requires weekly CPK monitoring [9]B2b[264]C4.
Duration of Therapy
Standard durations are 4 weeks for native valve IE and 6 weeks for prosthetic valve IE, counted from the first day of effective antibiotic therapy [120]D5. Shorter courses (2 weeks) are reserved for uncomplicated right-sided IE caused by highly susceptible organisms (e.g., MSSA) in patients without prosthetic material or metastatic foci [160]D5. For S. aureus IE, treatment should extend at least 4-6 weeks from the first negative blood culture [254]D5.
De-escalation to Oral Therapy
The POET trial demonstrated that switching to oral after a median of 17 days of IV therapy (range 10-28) is noninferior to continued IV therapy for left-sided IE caused by streptococci, E. faecalis, S. aureus, or coagulase-negative staphylococci (composite outcome 12.1% vs 9.0%; risk difference 3.1%, 95% CI -2.9% to 9.1%) [5]A1b. Oral regimens included 1 g q6h, 600 mg q12h, or clindamycin 600 mg q8h, selected based on susceptibility. Real-world cohorts confirm that oral step-down is safe in carefully selected patients who are hemodynamically stable, have controlled infection, and can tolerate oral medications [229]B2b[231]B2b.
Figure 1: Decision algorithm for oral step-down therapy based on POET trial eligibility criteria [5]A1b.
Monitoring and Treatment Failure
Persistent bacteremia beyond 7 days despite appropriate therapy warrants repeat echocardiography, search for metastatic foci, and consideration of surgical intervention [120]D5. Therapeutic drug monitoring (TDM) for beta-lactams (target fT>MIC 100%) and vancomycin (AUC/MIC ≥400) may improve outcomes in deep-seated infections [255]B2a[230]D5. For MRSA, daptomycin non-susceptibility can emerge during therapy; combination with ceftobiprole or a beta-lactam may restore susceptibility [264]C4[27]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Role of gentamicin in enterococcal IE | IDSA 2024 meta-analysis, adjunctive gentamicin offers no survival benefit and increases nephrotoxicity; ampicillin+ceftriaxone is preferred [1]A1a | Some European guidelines, still recommend gentamicin for synergy in prosthetic valve IE or when ceftriaxone cannot be used | Moderate | Most centers now avoid gentamicin; reserve for cases with high-level aminoglycoside resistance or intolerance to ceftriaxone |
| Optimal duration for prosthetic valve IE | AHA/ACC, 6 weeks from surgery [120]D5 | ESC, 6 weeks from first negative culture, with at least 2 weeks post-valve replacement | Mild | Both agree on 6 weeks total; timing of count start may differ but rarely changes |
Pearl: For E. faecalis IE, ampicillin plus ceftriaxone is the definitive regimen of choice, offering equivalent efficacy and superior renal safety compared with ampicillin plus gentamicin (NNT = 6 to prevent nephrotoxicity) [19]B2b[261]B2b; oral step-down therapy after ≥10 days of IV therapy is a safe option in stable patients with left-sided IE (POET trial) [5]A1b.
Antimicrobial Resistance and Stewardship
- ▸Acquired resistance, particularly to daptomycin, emerges rapidly during IE therapy due to high inocula; combination with a β-lactam prevents this emergence [188, 268].
- ▸Penicillin resistance in viridans group streptococci (MIC ≥4 μg/mL) is rare but manageable with vancomycin-based regimens plus early surgery [143, 271].
- ▸Molecular diagnostics (16S PCR, metagenomic sequencing) improve stewardship by identifying resistance genes directly from valves, earlier than culture-based AST [61, 267].
Resistance in infective endocarditis (IE) pathogens follows the selective pressure of prolonged, high-burden therapy. The same factors that make IE difficult to treat, large bacterial inocula in vegetations, biofilm formation, and prolonged bacteremia, also drive emergence of resistance during therapy [26]D5[188]D5. Two clinical patterns dominate: acquired resistance emerging during a single treatment course (e.g., non-susceptibility in S. aureus or enterococci) and intrinsic or pre-existing resistance that limits first-line options (e.g., penicillin-resistant viridans group streptococci, -resistant enterococci).
Mechanisms of Acquired Resistance
Daptomycin resistance is the most concerning acquired phenotype in IE. Prolonged exposure selects for mutations in mprF, cls, and walK, which alter cell membrane charge, fluidity, and lipid content, reducing daptomycin binding [26]D5[268]C4. A patient with end-stage renal disease developed MRSA IE with high-level daptomycin non-susceptibility after only two doses of dalbavancin; the resistant isolate carried walK and scrA mutations and showed reduced membrane fluidity [268]C4. In S. mitis-oralis, high-level daptomycin resistance can emerge within 1-3 days of in vitro passage at 5-20 μg/mL [188]D5. The combination of daptomycin plus prevented emergence of daptomycin resistance in vitro and in a rabbit endocarditis model [188]D5. Similarly, Abiotrophia and Granulicatella species develop high-level daptomycin resistance (MIC ≥ 256 μg/mL) rapidly during monotherapy, but plus daptomycin suppressed resistance emergence in vitro [48]D5.
Vancomycin resistance in enterococci (VRE) is mediated by vanA or vanB gene clusters. For E. faecium, daptomycin at 10-12 mg/kg/day is first-line, though MIC creep near the breakpoint of 4 mg/L reduces efficacy; in a rabbit model, 12 mg/kg showed superior vegetation clearance over 8 mg/kg against strains with MIC 4 mg/L [277]D5. Daptomycin plus ceftaroline is synergistic in vitro and in vivo against E. faecalis, even with high-level aminoglycoside resistance [278]D5.
Penicillin resistance in viridans group streptococci (VGS) is defined as MIC ≥4 μg/mL by CLSI. In a Spanish cohort, only 0.58% (9/1563) of streptococcal IE cases were penicillin-resistant, but all were treated with vancomycin-based regimens ± surgery; none of the 9 patients died during follow-up, suggesting that vancomycin plus surgery is effective [143]C4[271]B2b. Combination therapy with vancomycin plus gentamicin showed enhanced in vitro killing for highly resistant S. mitis (MIC 8 μg/mL) [32]C4. Alternative options include daptomycin plus ceftriaxone, which prevented emergence of resistance in S. mitis-oralis [188]D5.
β-lactamase production is rare but emerging. Kingella kingae, a cause of pediatric IE, produces TEM-1 β-lactamase in up to 25% of isolates from Minnesota and Iceland, conferring high-level penicillin resistance [276]C4. Corynebacterium striatum, increasingly reported in prosthetic valve IE, is frequently multidrug-resistant: one systematic review found 92% of isolates were resistant to penicillin, 87% to , and 28% to vancomycin, with aminoglycoside resistance in 55% [225]D5. C. diphtheriae remains susceptible to erythromycin but shows intermediate penicillin resistance in 98% of South African isolates (MIC90 0.5 μg/mL) [68]C4.
Multidrug-resistant organisms (MDROs) increasingly cause IE in healthcare-associated settings. Acinetobacter baumannii prosthetic valve IE, caused by extensively drug-resistant (XDR) strains, has been managed with combination colistin-based therapy plus valve replacement [30]C4. Elizabethkingia spp. cause IE with intrinsic resistance to multiple β-lactams and carbapenems; minocycline appears to play a key role, and combination therapy with or fluoroquinolones is required [274]C4. IE treated with ciprofloxacin plus bacteriophage cocktails showed synergy in ex vivo vegetation models, reducing phage resistance and restoring antibiotic sensitivity [275]D5.
Stewardship Principles in IE
for IE rests on four pillars: (i) rapid, accurate microbiologic identification with susceptibility testing, (ii) use of the narrowest effective regimen, (iii) avoidance of aminoglycosides when possible, and (iv) therapeutic drug monitoring (TDM) for agents with narrow therapeutic indices.
Molecular diagnostics improve stewardship. 16S rRNA PCR/Sanger sequencing on resected valves plus molecular antibiogram (genotypic resistance prediction from extracted DNA) increased microbiologic diagnosis from 55% (blood culture) to 88% and allowed earlier targeted therapy [267]B2b. Metagenomic sequencing (shotgun or 16S targeted) on plasma cell-free DNA provides culture-free identification within 24-48 hours [61]B2b.
For penicillin-susceptible VGS (MIC ≤0.12 μg/mL), penicillin G 12-18 MU/day or ceftriaxone 2 g/day for 4 weeks is preferred [204]B3b. For penicillin-resistant VGS, vancomycin (target trough 15-20 μg/mL) plus gentamicin 3 mg/kg/day is guideline-recommended [269]C4. Daptomycin 10-12 mg/kg/day is reserved for vancomycin-allergic or refractory cases, but TDM of daptomycin, monitoring trough levels to avoid myopathy, is advised, especially in renal impairment [238]D5.
For E. faecalis, ampicillin 12 g/day plus ceftriaxone 2 g q12h has replaced ampicillin-gentamicin as the regimen of choice, reducing nephrotoxicity while maintaining efficacy [19]B2b[261]B2b. Dual β-lactam synergy is predictable by checkerboard or gradient diffusion strip testing, with 92% sensitivity and 93% specificity for predicting benzylpenicillin-ceftriaxone synergy by layered GDS [51]B2b. For borderline-penicillin-resistant, ampicillin-susceptible E. faecalis (penicillin MIC 4-8 μg/mL), ceftobiprole alone shows in vitro activity comparable to ampicillin-ceftriaxone, offering a possible single-agent alternative [46]D5.
Combination therapy for S. aureus IE remains controversial. Daptomycin plus ceftaroline demonstrated synergy in experimental E. faecalis IE and is advocated for MRSA IE with reduced daptomycin susceptibility [278]D5[282]D5. Bicarbonate (NaHCO₃) supplementation at physiological concentrations resensitizes 40-60% of MRSA strains to oxacillin and cefazolin in vitro, a phenotype predicted by susceptibility testing in bicarbonate-supplemented media [185]D5. Anti-staphylococcal lysins (e.g., exebacase, lysostaphin) show synergy with β-lactams and daptomycin, rapidly killing MRSA in biofilms and resensitizing resistant strains [186]D5[195]C4.
Controversies and Guideline Disagreement
| Question | Position A (AHA/IDSA) | Position B (ESC) | Strength | Implication |
|---|---|---|---|---|
| Vancomycin vs. daptomycin for MRSA IE with MIC 1-2 mg/L | Vancomycin first-line (AHA) | High-dose daptomycin (10-12 mg/kg) preferred if MIC >1 (ESC) | Moderate | TDM and MIC-guided choice is prudent; daptomycin is associated with fewer relapses but higher cost |
| Aminoglycoside duration for penicillin-resistant VGS | 2-week gentamicin with vancomycin (AHA) | No explicit recommendation; daptomycin-based options preferred (ESC) | Weak | Expert opinion; consider renal function and resistance risk |
| Dual β-lactam vs. ampicillin-gentamicin for E. faecalis | Ampicillin-ceftriaxone is first-line (both AHA and ESC) | Ampicillin-gentamicin reserved for or intolerance (ESC) | Strong | Consensus supports ampicillin-ceftriaxone; avoid gentamicin if possible |
| Role of combination therapy for MSSA IE | β-lactam monotherapy (AHA) | Some experts add an aminoglycoside for first 3-5 days in native valve IE (ESC) | Weak | No mortality benefit with addition; toxicity offsets any gain |
Pearl: The emergence of resistance during IE therapy is driven by high bacterial inocula and prolonged treatment; daptomycin resistance can arise within days of monotherapy, making combination regimens (daptomycin + β-lactam or ceftriaxone) essential for strains at risk, while stewardship centered on rapid molecular diagnostics and avoidance of nephrotoxic synergists reduces both resistance and adverse outcomes [26]D5[188]D5[267]B2b[282]D5.
| Pathogen | Resistance Mechanism | MIC Breakpoint | Preferred Regimen | Alternative Regimen |
|---|---|---|---|---|
| Staphylococcus aureus (MRSA) | PBP2a (mecA) | Oxacillin MIC ≥4 μg/mL | Vancomycin (trough 15-20 μg/mL) or daptomycin 10-12 mg/kg/day | Daptomycin + ceftaroline; ceftobiprole |
| S. aureus (daptomycin non-susceptible) | mprF, cls, walK mutations | DAP MIC >1 μg/mL | Daptomycin 12 mg/kg + ceftaroline 600 mg q12h | Vancomycin + ceftaroline; lysostaphin [186]D5 |
| Enterococcus faecium (VRE) | vanA/vanB | Vancomycin MIC ≥32 μg/mL | Daptomycin 10-12 mg/kg/day | Daptomycin + ceftaroline; linezolid |
| Enterococcus faecalis (penicillin-R, ampicillin-S) | PBP5 mutations | Penicillin MIC 4-8 μg/mL | Ampicillin 12 g/day + ceftriaxone 2 g q12h | Ceftobiprole (single agent) [46]D5 |
| Viridans group streptococci (penicillin-R) | PBP alterations | PEN MIC ≥4 μg/mL | Vancomycin + gentamicin × 2 weeks | Daptomycin + ceftriaxone [188]D5 |
| Corynebacterium striatum | Multidrug resistance (β-lactams, fluoroquinolones, aminoglycosides) | Variable | Vancomycin ± rifampin | Daptomycin; linezolid |
| Kingella kingae | TEM-1 β-lactamase | PEN MIC >2 μg/mL | Cefotaxime or ceftriaxone | Vancomycin + gentamicin |
| Elizabethkingia spp. | Intrinsic β-lactamases, carbapenemases | Variable | Minocycline + rifampin or ciprofloxacin | Trimethoprim-sulfamethoxazole |
| Pseudomonas aeruginosa (MDR/XDR) | Multiple β-lactamases, efflux pumps | Variable | Ceftolozane-tazobactam + colistin; phage-antibiotic cocktails [275]D5 | Combination therapy; valve replacement |
Complications and Supportive Care
- ▸Septic emboli affect the CNS, spleen, kidneys, and lungs in ≥20% of IE cases, and mycotic aneurysm rupture carries >50% mortality.
- ▸Heart failure from valvular destruction is the most common cardiac complication and mandates early surgical consultation.
- ▸Acute kidney injury from antimicrobials can be reduced by avoiding aminoglycosides when possible and targeting vancomycin AUC/MIC >400.
- ▸Hospital-acquired complications such as DVT, pressure injury, and drug withdrawal require dedicated prophylaxis protocols.
Even with appropriate antimicrobial and surgical therapy, infective endocarditis carries a high burden of complications that directly drive mortality and morbidity. The clinician must maintain vigilance for both septic embolic events and the deleterious effects of prolonged hospitalization. of these complications is as critical as treating the infection itself.
Embolic and Metastatic Complications
Septic embolism is a hallmark of IE, occurring in 20-50% of cases [13]D5[172]B3b. The central nervous system is most frequently affected: embolic stroke complicates 15-35% of cases, with a predilection for the middle cerebral artery territory. Splenic infarction (10-20%) and splenic abscess (3-5%) require dedicated imaging (CT or MRI) for detection; a splenic abscess mandates either percutaneous drainage or splenectomy to achieve source control [172]B3b. and of the intracranial or visceral arteries each occur in approximately 5% of patients. Rupture of a mycotic aneurysm carries a mortality exceeding 50%, justifying early angiographic screening in patients with persistent headache or focal neurologic deficits [13]D5[172]B3b. Septic pulmonary emboli are characteristic of right-sided IE, particularly in persons who inject drugs [100]A1a.
Cardiac Complications
Heart failure represents the most common cardiac complication, occurring in 30-60% of patients [43]B2b. It results from acute valvular regurgitation, prosthetic valve dehiscence, or intracardiac fistula formation. Perivalvular abscess complicates 10-40% of prosthetic valve IE and mandates surgical debridement [43]B2b[73]B2b. Conduction abnormalities, new-onset PR prolongation or complete heart block, suggest extension of infection into the interventricular septum and require urgent echocardiographic evaluation [17]A1c.
Systemic Complications and Antimicrobial Adverse Effects
Acute kidney injury (AKI) arises from multiple mechanisms: septic shock, radiocontrast exposure, nephrotoxic (e.g., gentamicin, ). Aminoglycoside-induced AKI occurs in 15-25% of treated patients; the incidence is nearly halved with - versus ampicillin-gentamicin [19]B2b[261]B2b. Vancomycin therapy targeting an AUC/MIC ratio >400 reduces nephrotoxicity compared to trough-based dosing [137]B2b. Immune complex-mediated glomerulonephritis, while less common in the antibiotic era, can mimic acute nephritic syndrome [10]A1c. Drug fever, rash, and Clostridioides difficile colitis each complicate the course in 5-10% of patients [204]B3b[289]B2b.
Hospital-Acquired Complications
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Central-line associated bloodstream infection | 5-10 per 1000 catheter-days | Strict insertion bundle; daily line necessity review | Remove catheter; culture-directed antibiotics |
| (VAP) | 5-15% of intubated patients | -of-bed elevation; oral chlorhexidine; daily sedation interruption | Empiric broad-spectrum antibiotics per local antibiogram |
| Pressure injury | 8-20% | Risk assessment (Braden scale); repositioning q2h; pressure-relieving surfaces | Stage-appropriate wound care; debridement if necrotic |
| Deep vein thrombosis (DVT) | 10-20% | Pharmacologic prophylaxis: 40 mg subcutaneously daily or unfractionated 5000 U subcutaneously q8-12h | Therapeutic anticoagulation for proximal DVT; monitor for intracranial hemorrhage |
| Urinary tract infection (catheter-associated) | 3-8 per 1000 catheter-days | Avoid catheter unless essential; remove at 24h | Culture-directed antibiotics; remove catheter |
| Drug withdrawal in opioid-tolerant patients | 60-90% of persons who inject drugs | Protocol-driven methadone or buprenorphine initiation; adjunctive clonidine | Standardized withdrawal management to prevent against medical advice discharge [13]D5 |
Pain Management
Pain in IE arises from septic emboli (pleuritic, abdominal, or bone pain), from post-thoracotomy incision, and from prolonged immobility. A multimodal analgesic approach is recommended. For moderate-to-severe pain in opioid-naïve patients, 2-4 mg intravenously q2-4h PRN is first-line. For post-surgical pain, patient-controlled with IV is effective. For persons who inject drugs with opioid tolerance, the required dose is often 3-5× the standard dose; a consultation with addiction medicine or pain management is indicated [13]D5[105]B2b. Adjunctive non-opioid agents, acetaminophen 1000 mg orally q6h, gabapentin 300-600 mg orally three times daily, can reduce opioid requirements [13]D5.
Rehabilitation
Functional decline is common after prolonged ICU stay and cardiac surgery. Early mobilization, initiated as soon as hemodynamic stability is achieved (typically within 48 hours of extubation), reduces muscle wasting and shortens hospital length of stay. A structured physical therapy program, including range-of-motion exercises, progressive ambulation, and inspiratory muscle training, should be provided. Occupational therapy addresses activities of daily living. Comprehensive cardiac rehabilitation is indicated for all patients after valve surgery, beginning 4-6 weeks post-operatively [126]C4.
Pearl: Septic embolic events and heart failure drive the majority of IE-related mortality; the clinician's index of suspicion for these complications must remain high, and in patients with , untreated withdrawal is a leading cause of treatment abandonment [13]D5[100]A1a.
Prognosis and Natural History
- ▸In-hospital mortality for infective endocarditis is 20-25%, rising to 40-50% for S. aureus and prosthetic valve infections
- ▸Valve surgery when indicated reduces 6-month mortality from 48% to 32% (NNT = 6); early surgery within 48 hours in select patients reduces embolic-death composite from 28% to 3% (NNT = 4)
- ▸Long-term suppression (SAT) reduces relapse in unresectable prosthetic infection from 40% to 12% (NNT = 4)
Untreated left-sided infective endocarditis is nearly universally fatal, with historical series reporting 100% mortality within months from uncontrolled sepsis, progressive valvular destruction, or embolic catastrophe [117]D5. Contemporary antimicrobial and surgical therapy has transformed this trajectory, yet in-hospital mortality remains 20% to 25% overall, rising to 30% to 40% for prosthetic valve endocarditis and 40% to 50% for Staphylococcus aureus infection [41]B2b[120]D5. The natural history proceeds through three overlapping phases: acute septic dissemination (days to week), valvular and perivalvular structural injury (weeks), and late embolic or immunologic sequelae (weeks to months).
Time Course and Nadir
Symptom onset to diagnosis averages 2 to 4 weeks in subacute presentations and less than 1 week in acute S. aureus endocarditis [127]B2b[302]B2b. The rate of major embolic events peaks in the first 2 weeks of effective therapy, dropping sharply after valve sterilization, although vegetation size >10 mm and mitral location carry sustained embolic risk up to 30% even during treatment [104]A1b[212]B2b. The nadir for clinical deterioration occurs between hospital days 5 and 14, the period during which 60% of surgery-eligible patients who do not undergo early operation experience progression of heart failure or paravalvular abscess [43]B2b[104]A1b.
Predictors of Mortality
Nine independent predictors consistently emerge across large cohorts, integrated into validated risk scores such as Risk-E and ICE-PCS [33]B3b[222]B3b. The strongest are:
- Heart failure ( III-IV), hazard ratio (HR) 2.5 to 3.1; 1-year mortality with medically managed HF approaches 50% [43]B2b[218]B2b.
- Staphylococcus aureus infection, 30-day mortality 30% (HR 1.7), largely driven by sepsis and multi-organ failure [3]B2b[302]B2b.
- Prosthetic valve involvement, in-hospital mortality 25-40%, double that of native valve IE [41]B2b.
- Septic shock at presentation, mortality 45% to 60% [218]B2b.
- Major embolic events (stroke, visceral embolism), 1-year mortality rises from 20% to 45% (HR 2.3) [113]B2b[304]B2b.
| Variable | Approximate 6-Month Mortality | Strength of Association (HR; 95% CI) |
|---|---|---|
| No surgery when indicated | 40-50% | HR 2.8 (2.0-3.9) [43]B2b[212]B2b |
| S. aureus + septic shock | 55-65% | HR 3.1 (2.2-4.4) [218]B2b |
| Prosthetic valve endocarditis | 30-35% | HR 1.8 (1.4-2.3) [41]B2b |
| Intracranial rupture | 50% | HR 2.3 (1.5-3.7) [113]B2b |
| Corticosteroid therapy (contraindicated) | 2-fold increase | no precise HR; consensus [117]D5 |
Surgery and Survival Benefit
Valve surgery when indicated reduces 6-month mortality from 48% to 32% (absolute risk reduction 16 percentage points; NNT = 6), with the greatest benefit in patients with heart failure, paravalvular abscess, or large vegetations [43]B2b[104]A1b. Early surgery (within 48 hours) in the EASE trial reduced the composite of in-hospital death and embolic events from 28% to 3% (HR 0.10, 95% CI 0.03-0.43) in patients with severe valve disease and vegetation >10 mm [104]A1b. However, mortality benefit is lost in patients with prohibitive surgical risk (EuroSCORE II >20%) or active cerebral hemorrhage [212]B2b[304]B2b.
Long-Term Outcomes
Among 1-year survivors, 5-year survival is 70-75% for native valve and 50-60% for prosthetic valve IE, with late deaths primarily from heart failure (40%), reinfection (15%), and non-cardiovascular causes (30%) [41]B2b[228]B2b[306]B2b. Relapse rates are 2% to 6% for streptococcal IE but reach 10% to 15% for enterococcal and staphylococcal IE, particularly when an intracardiac device remains [133]B2b[189]C4[287]C4. Long-term suppressive antimicrobial therapy (SAT), typically with oral , , or , reduces relapse in patients with unresectable prosthetic material from 40% to 12% over 2 years (NNT = 4), though prospective randomized data are lacking [287]C4. Health-related quality of life at 12 months remains impaired: the EQ-5D visual analogue scale median score is 65/100 (vs 80/100 in age-matched controls), with fatigue and dyspnea the most frequent residual symptoms [306]B2b.
Controversies and Guideline Disagreement
| Question | Position A (AHA/ACC) | Position B (ESC) | Strength | Implication |
|---|---|---|---|---|
| Surgery in elderly (≥80 y) without HF | Surgery only if definitive structural complication [212]B2b | Age alone not a contraindication; consider frailty [212]B2b | Both position statements, no RCT | Individualized decision; CCI >5 predicts no survival benefit [212]B2b |
| Anticoagulation during active IE | Hold all anticoagulation unless mechanical valve [41]B2b | Continue for mechanical valves with INR monitoring [41]B2b | Guideline disagreement | Higher hemorrhagic conversion risk in septic emboli; must balance [113]B2b |
| Duration of oral suppression for prosthetic IE | Not addressed | Consider lifelong SAT for unresectable infection [287]C4 | ESC expert opinion | 40-50% relapse without SAT; weak evidence base [287]C4 |
Pearl: Untreated IE is uniformly fatal; early surgery within 48 hours in appropriate candidates reduces the 6-week embolic-death composite from 28% to 3% (NNT = 4), and valve surgery overall yields a 16% absolute mortality reduction (NNT = 6), yet septic shock and S. aureus continue to drive the majority of the remaining 20-25% in-hospital mortality [43]B2b[104]A1b[218]B2b.
Prevention, Infection Control and Special Populations
- ▸Antibiotic prophylaxis for IE is recommended only for highest-risk patients (prosthetic valves, previous IE, specific CHD) undergoing dental procedures; amoxicillin 2 g (50 mg/kg in children) is first-line, with anaphylaxis risk <0.001% [141, 315].
- ▸IE in pregnancy carries maternal mortality up to 30% and fetal loss in 25%; beta-lactams are safe, and delivery should be planned at a tertiary center [59, 110].
- ▸Immunocompromised patients with IE often present with atypical pathogens (Kingella, Spiroplasma, Listeria, Coxiella) and require molecular diagnostics and prolonged combination therapy [40, 163, 265].
Antibiotic prophylaxis for infective endocarditis remains one of the most debated areas in cardiovascular medicine, with guideline divergence between the AHA/ESC and NICE reflecting conflicting interpretations of observational data [103]B2b[123]B2c[315]D5. AHA/ESC recommend prophylaxis only for the highest-risk patients, those with prosthetic valves, previous IE, or specific congenital heart disease, undergoing dental procedures involving gingival manipulation. NICE recommends no prophylaxis for any patient. A Swedish nationwide cohort found no increase in oral streptococcal IE after cessation of prophylaxis [103]B2b, while an English interrupted time-series reported a subsequent rise in IE incidence, though causality remains contested [123]B2c. Adverse reactions to single-dose 3 g are rare ( rate 0.001%), whereas clindamycin carries a higher risk of C. difficile infection [141]B2c. Daily oral hygiene and regular dental visits are equally critical, as everyday bacteremia likely contributes more to IE risk than procedural bacteremia [307]B3b. For TAVI, cefazolin prophylaxis alone may be insufficient given the predominance of enterococci; recent PK data suggest adding an agent with enterococcal activity [311]C4. reduces the risk of pneumococcal IE, including Austrian syndrome [323]C4. Standard transmission-based precautions apply: contact precautions for MRSA or VRE IE, droplet precautions for respiratory pathogens.
Pediatrics
IE in children is rare but predominantly affects those with congenital heart disease, especially after surgical repair. Prophylaxis follows adult guidelines with weight-based dosing: amoxicillin 50 mg/kg orally 1 hour before the procedure [322]B2a. Among children with S. aureus bacteremia, the prevalence of IE is 8.8% [309]B2b. Echocardiography is essential but may be technically challenging; transesophageal imaging is reserved for older children or when transthoracic windows are inadequate. Treatment uses age-adjusted antibiotic doses (e.g., 200 mg/kg/day IV divided q4h, gentamicin 7.5 mg/kg/day IV divided q8h). Surgical intervention follows the same indications as adults. Long-term developmental follow-up is warranted after severe IE.
Pregnancy
IE in pregnancy is rare (0.006% of deliveries) but increasing with the opioid epidemic [59]B2b[110]B2c. Maternal mortality reaches 30%, and fetal loss occurs in up to 25% of cases [59]B2b[122]C4. Streptococci and staphylococci are the most common pathogens [122]C4. Beta-lactams (ampicillin 2 g IV q4h, 2 g IV q24h) are first-line and safe in pregnancy. Aminoglycosides require therapeutic drug monitoring due to altered renal clearance; troughs should be monitored. Surgery during pregnancy carries high fetal risk but is indicated for heart failure, uncontrolled infection, or large vegetations. Delivery should be planned after maternal stabilization, ideally at a tertiary center with cardiothoracic surgery capability. Most are safe during , though tetracyclines and fluoroquinolones should be avoided.
Elderly
IE in elderly patients is increasingly associated with degenerative valve disease, prosthetic valves, and TAVI [73]B2b[314]D5. Enterococci are more common, and presentation may be atypical (confusion, falls, anorexia). The modified Duke criteria have lower sensitivity in this population; 18F-FDG PET/CT is often needed to confirm prosthetic valve IE [314]D5. Surgery is performed less frequently due to frailty and comorbidities, contributing to higher mortality [73]B2b. Antibiotic doses require renal adjustment (e.g., gentamicin 3 mg/kg IV q24h if CrCl <30 mL/min). Austrian syndrome (pneumococcal pneumonia, meningitis, IE) can occur in immunocompetent elderly and demands prompt recognition [323]C4.
Immunocompromised
Immunocompromised patients, including those with HIV, solid organ transplant, hematologic malignancies, or primary immunodeficiencies, are at risk for IE from atypical pathogens: Kingella kingae [163]C4, Spiroplasma apis [40]C4, Listeria monocytogenes [265]C4, Coxiella burnetii [201]C4, and Corynebacterium diphtheriae [68]C4. Patients with have a 3-fold higher risk of S. aureus IE [291]B2b. A low threshold for investigation is warranted; blood cultures should be held for prolonged incubation, and molecular diagnostics (16S rRNA PCR, metagenomic sequencing) are often necessary [40]C4[163]C4. Prophylaxis for dental procedures may be considered on a case-by-case basis, though no formal guidelines exist. Treatment typically requires longer courses (6-8 weeks) and combination therapy, with attention to drug-drug interactions (e.g., with immunosuppressants). Prognosis is worse due to delayed diagnosis and underlying immune dysfunction.
Pearl: Antibiotic prophylaxis for IE is recommended only for the highest-risk patients undergoing dental procedures, with amoxicillin 2 g (50 mg/kg in children) as first-line; IE in pregnancy carries maternal mortality up to 30% and requires beta-lactam-based regimens with multidisciplinary planning [59]B2b[110]B2c[315]D5.
References
- [1]
Prosty C, Sorin M, Katergi K et al.. “Revisiting the Evidence Base That Informs the Use of Adjunctive Therapy for Enterococcus faecalis Endocarditis: A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39041860 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [2]
Fowler VG, Das AF, Lipka-Diamond J et al.. “Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38297916 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History - [3]
Strömdahl M, Hagman K, Hedman K et al.. “Time to Staphylococcus aureus Blood Culture Positivity as a Risk Marker of Infective Endocarditis: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39707905 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [4]
Kurland S, Furebring M, Löwdin E et al.. “Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40515674 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [5]
Iversen K, Ihlemann N, Gill SU et al.. “Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.” The New England journal of medicine (2018). PMID: 30152252 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [6]
Chesdachai S, Baddour LM, Tabaja H et al.. “State-of-the-Art Review: Complexities in Cardiac Implantable Electronic Device Infections: A Contemporary Practical Approach.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39908172 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [7]
Falagas ME, Manta KG, Ntziora F et al.. “Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.” The Journal of antimicrobial chemotherapy (2006). PMID: 16735427 ↗
L5SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [8]
Falagas ME, Matthaiou DK, Bliziotis IA. “The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.” The Journal of antimicrobial chemotherapy (2006). PMID: 16501057 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management - [9]
Bhavnani SM, Ambrose PG, Hammel JP et al.. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial agents and chemotherapy (2015). PMID: 26711755 ↗
L2RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [10]
Meena J, Sinha A, Krishnasamy S et al.. “AsPNA Clinical Practice Guidelines for the management of infection-related glomerulonephritis.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 41627401 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Complications - [11]
Tong SY, Davis JS, Eichenberger E et al.. “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.” Clinical microbiology reviews (2015). PMID: 26016486 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [12]
Nørskov-Lauritsen N. “Classification, identification, and clinical significance of Haemophilus and Aggregatibacter species with host specificity for humans.” Clinical microbiology reviews (2014). PMID: 24696434 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup - [13]
Masters J, Goodman-Meza D, Russell D et al.. “Bacterial and fungal infections in persons who inject drugs.” Clinical microbiology reviews (2025). PMID: 40511913 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications - [14]
Spaulding AR, Salgado-Pabón W, Kohler PL et al.. “Staphylococcal and streptococcal superantigen exotoxins.” Clinical microbiology reviews (2013). PMID: 23824366 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Complications - [15]
Speziale P, Foster TJ, Arciola CR. “The endothelium at the interface between tissues and Staphylococcus aureus in the bloodstream.” Clinical microbiology reviews (2025). PMID: 39807893 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis - [16]
Corvec S. “Clinical and Biological Features of Cutibacterium (Formerly Propionibacterium) avidum, an Underrecognized Microorganism.” Clinical microbiology reviews (2018). PMID: 29848774 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [17]
Fowler VG, Durack DT, Selton-Suty C et al.. “The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37138445 ↗
L1OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric and Acute Management, Complications - [18]
Bock M, Theut AM, van Hasselt JGC et al.. “Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36947131 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [19]
Fernández-Hidalgo N, Almirante B, Gavaldà J et al.. “Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23392394 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [20]
Goehringer F, Soudant M, Alauzet C et al.. “Single- Versus Multiple-sampling Strategy for Blood Cultures in the Diagnosis of Infective Endocarditis: The Prospective Multicenter UniEndo Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40176205 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup - [21]
Panagides V, Cuervo G, Llopis J et al.. “Infective Endocarditis After Transcatheter Versus Surgical Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37552784 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History - [22]
Arnold CJ, Johnson M, Bayer AS et al.. “Candida infective endocarditis: an observational cohort study with a focus on therapy.” Antimicrobial agents and chemotherapy (2015). PMID: 25645855 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [23]
Cahill TJ, Prendergast BD. “Infective endocarditis.” Lancet (London, England) (2015). PMID: 26341945 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prevention, Infection Control and Special Populations - [24]
Chaldoupis AE, Petrakis V, Ioannou P et al.. “Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41665791 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Definitive Therapy, Duration and De-escalation, Complications - [25]
Han QJ, Henson DM, Yucel E et al.. “Evaluation of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Criteria in a Multicenter Cohort of Patients With Intravenous Drug Use: A Retrospective Study.” Open forum infectious diseases (2025). PMID: 40124200 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms - [26]
Heidary M, Khosravi AD, Khoshnood S et al.. “Daptomycin.” The Journal of antimicrobial chemotherapy (2018). PMID: 29059358 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [27]
Kullar R, Sakoulas G, Deresinski S et al.. “When sepsis persists: a review of MRSA bacteraemia salvage therapy.” The Journal of antimicrobial chemotherapy (2015). PMID: 26565015 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [28]
Verhagen DW, Vedder AC, Speelman P et al.. “Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations.” The Journal of antimicrobial chemotherapy (2006). PMID: 16549513 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [29]
Cuervo G, Chesdachai S, Hindy JR et al.. “Clinical Features of Adult Patients with Isolated Pulmonary Valve Endocarditis: A Systematic Review.” Microorganisms (2026). PMID: 42354833 ↗
L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History - [30]
Salvati A, Alessio L, Trombaccia G et al.. “Prosthetic Valve Endocarditis by Acinetobacter baumannii: Case Report and Systematic Descriptive Review.” Pathogens (Basel, Switzerland) (2026). PMID: 42347193 ↗
L4SR_OBSCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [31]
Lowenthal A, Weisblum-Neuman H, Birk E et al.. “Clinical Features and Comparison of Kingella and Non-Kingella Endocarditis in Children, Israel.” Emerging infectious diseases (2021). PMID: 33622463 ↗
L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation - [32]
Pericàs JM, Nathavitharana R, Garcia-de-la-Mària C et al.. “Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.” Antimicrobial agents and chemotherapy (2019). PMID: 31182540 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [33]
Garibay-Padilla IE, Hernandez-Del Río JE, Orozco-Sepulveda DE et al.. “In-Hospital Mortality Predictors and a Bayesian Weighted-Incidence Antibiogram in Infective Endocarditis: A Seven-Year Cohort Study from a Mexican Tertiary University Hospital.” Medical sciences (Basel, Switzerland) (2026). PMID: 42201006 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [34]
Oterino-Moreira I, Candel-González FJ, Pérez-Encinas M et al.. “Association between antimicrobial resistance and in-hospital mortality in adults with bacterial infective endocarditis: A nationwide cohort study.” International journal of antimicrobial agents (2026). PMID: 41974287 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [35]
Solera JT, Aparicio-Minguijón E, Domínguez-Pérez L et al.. “Baseline Antithrombotic Therapy and Intracranial Hemorrhage Risk in Infective Endocarditis: A Multicenter Prospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41643743 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms - [36]
Lin EY, Tsigrelis C, Baddour LM et al.. “Candidatus Bartonella mayotimonensis and endocarditis.” Emerging infectious diseases (2010). PMID: 20202430 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup - [37]
Vetterli D, Zennaro M, Tacchini V et al.. “Next-Generation Sequencing Techniques to Diagnose Culture-Negative Subacute Native Aortic Endocarditis.” Emerging infectious diseases (2025). PMID: 40562730 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup - [38]
Tasher D, Raucher-Sternfeld A, Tamir A et al.. “Bartonella quintana, an Unrecognized Cause of Infective Endocarditis in Children in Ethiopia.” Emerging infectious diseases (2017). PMID: 28730981 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [39]
Uçkay I, Rohner P, Bolivar I et al.. “Streptococcus sinensis endocarditis outside Hong Kong.” Emerging infectious diseases (2007). PMID: 17953105 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [40]
Etienne N, Bret L, Le Brun C et al.. “Disseminated Spiroplasma apis Infection in Patient with Agammaglobulinemia, France.” Emerging infectious diseases (2018). PMID: 30457541 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prevention, Infection Control and Special Populations - [41]
Wang A, Athan E, Pappas PA et al.. “Contemporary clinical profile and outcome of prosthetic valve endocarditis.” JAMA (2007). PMID: 17392239 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [42]
Toyoda N, Chikwe J, Itagaki S et al.. “Trends in Infective Endocarditis in California and New York State, 1998-2013.” JAMA (2017). PMID: 28444279 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prevention, Infection Control and Special Populations - [43]
Kiefer T, Park L, Tribouilloy C et al.. “Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure.” JAMA (2011). PMID: 22110106 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [44]
Alberti MO, Hindler JA, Humphries RM. “Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans.” Antimicrobial agents and chemotherapy (2015). PMID: 26666926 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [45]
Bleick CR, Van Helden SR, Berti AD et al.. “Optimizing phage-antibiotic combinations: impact of administration order against daptomycin non-susceptible (DNS) MRSA clinical isolates.” Antimicrobial agents and chemotherapy (2025). PMID: 41251374 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [46]
Funk OG, Li J, Khan I et al.. “Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates.” Antimicrobial agents and chemotherapy (2025). PMID: 41277848 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [47]
Bellouard R, Deschanvres C, Deslandes G et al.. “Population Pharmacokinetic Study of Cefazolin Dosage Adaptation in Bacteremia and Infective Endocarditis Based on a Nomogram.” Antimicrobial agents and chemotherapy (2019). PMID: 31307987 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [48]
Cañas MA, Téllez A, García de la Mària C et al.. “Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis.” Antimicrobial agents and chemotherapy (2021). PMID: 34252304 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [49]
Watson A, Oh JT, Sauve K et al.. “Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis.” Antimicrobial agents and chemotherapy (2019). PMID: 31332073 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management - [50]
Cojutti PG, Gatti M, Tedeschi S et al.. “Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.” Antimicrobial agents and chemotherapy (2025). PMID: 39992102 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History - [51]
Gregson A, Mowlaboccus S, Sudeep SM et al.. “Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes.” The Journal of antimicrobial chemotherapy (2025). PMID: 41105431 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [52]
Luque Paz D, Turban A, Guérin F et al.. “Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates.” The Journal of antimicrobial chemotherapy (2025). PMID: 40720087 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [53]
Tala-Ighil T, Royer G, Lepeule R et al.. “Clinical features and medical-surgical management overweight the inoculum effect and genotypic characteristics of MSSA in infective endocarditis.” The Journal of antimicrobial chemotherapy (2025). PMID: 40205923 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [54]
Lalanne S, Guérin F, Flécher E et al.. “Diffusion of amoxicillin into heart valves from infective endocarditis patients.” The Journal of antimicrobial chemotherapy (2022). PMID: 36378501 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [55]
Ashrin A, Hagenimana C, Jacquier H et al.. “Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium.” The Journal of antimicrobial chemotherapy (2026). PMID: 41247078 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation - [56]
Kato H, Kitaura T, Noma H et al.. “Risk factors for community-acquired metastatic infections without infective endocarditis in patients with Staphylococcus aureus bacteremia: A retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42162662 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications - [57]
Sulaiman D, Moqbil S, Moqbel O. “Dual Infection with dengue virus and infective endocarditis leading to brain abscess, multiorgan infarctions, and horner syndrome: a case report with literature review.” BMC cardiovascular disorders (2026). PMID: 41876992 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms - [58]
Shah S, Clarke LG, Shields RK. “Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 36968963 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [59]
Shapero K, El-Dalati S, Berlacher K et al.. “Outcomes of Endocarditis in Pregnancy: A Single-Center Experience.” Open forum infectious diseases (2023). PMID: 37779596 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations - [60]
Bläckberg A, Falk L, Oldberg K et al.. “Infective Endocarditis Due to Corynebacterium Species: Clinical Features and Antibiotic Resistance.” Open forum infectious diseases (2021). PMID: 33738317 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Antimicrobial Resistance and Stewardship - [61]
Flurin L, Fisher CR, Wolf MJ et al.. “Comparison of Blood-Based Shotgun and Targeted Metagenomic Sequencing for Microbiological Diagnosis of Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 38075017 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [62]
Alonso-Menchén D, Bouza E, Valerio M et al.. “Non-nosocomial Healthcare-Associated Infective Endocarditis: A Distinct Entity? Data From the GAMES Series (2008-2021).” Open forum infectious diseases (2023). PMID: 37564744 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [63]
Halavaara M, Martelius T, Anttila VJ et al.. “Three Separate Clinical Entities of Infective Endocarditis-A Population-Based Study From Southern Finland 2013-2017.” Open forum infectious diseases (2020). PMID: 32913877 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [64]
Huang G, Gupta S, Davis KA et al.. “Infective Endocarditis Guidelines: The Challenges of Adherence-A Survey of Infectious Diseases Clinicians.” Open forum infectious diseases (2020). PMID: 32964063 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms - [65]
Cuervo G, Rombauts A, Caballero Q et al.. “Twenty-Year Secular Trends in Infective Endocarditis in a Teaching Hospital.” Open forum infectious diseases (2018). PMID: 30167435 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [66]
Woller Iii JA, Walsh VL, Robichaux C et al.. “Predictors of Surgical Intervention in Dialysis Patients With Infective Endocarditis.” Open forum infectious diseases (2018). PMID: 30539033 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [67]
Watt G, Pachirat O, Baggett HC et al.. “Infective endocarditis in northeastern Thailand.” Emerging infectious diseases (2014). PMID: 24572588 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [68]
du Plessis M, Mikhari R, de Gouveia L et al.. “Corynebacterium diphtheriae Infections, South Africa, 2015-2023.” Emerging infectious diseases (2025). PMID: 40023798 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations - [69]
Larsen J, Schønheyder HC, Lester CH et al.. “Porcine-origin gentamicin-resistant Enterococcus faecalis in humans, Denmark.” Emerging infectious diseases (2010). PMID: 20350387 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [70]
Pierson S, Chabannes M, Lang S et al.. “Case Report: Successful treatment of Bartonella henselae-associated crescentic glomerulonephritis in renal transplant recipient.” Frontiers in medicine (2026). PMID: 42292227 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management - [71]
Chirouze C, Alla F, Fowler VG et al.. “Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25389255 ↗
L2COHORTCited in: Microbiology and Pathogenesis - [72]
Henriet SSV, Langereis JD, Lo SW et al.. “Endocarditis Caused by Nontypeable Streptococcus pneumoniae.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35134152 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup - [73]
Strange JE, Østergaard L, Køber L et al.. “Patient Characteristics, Microbiology, and Mortality of Infective Endocarditis After Transcatheter Aortic Valve Implantation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37470442 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations - [74]
Lindberg H, Berge A, Jovanovic-Stjernqvist M et al.. “Performance of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis in Relation to the Modified Duke Criteria and to Clinical Management-Reanalysis of Retrospective Bacteremia Cohorts.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38330240 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [75]
Oldberg K, Rasmussen M. “Make Modern Microbiology Matter More in the 2023 European Society of Cardiology Guidelines for the Management of Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38655671 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [76]
McCarthy NL, Baggs J, See I et al.. “Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012-2017.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31907515 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [77]
Anavekar NS, Tleyjeh IM, Anavekar NS et al.. “Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17407036 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [78]
Zhou X, Huang Y, Zhang W et al.. “Leuconostoc as an emerging pathogen in humans: an updated systematic review.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40965618 ↗
L4SR_OBSCited in: Microbiology and Pathogenesis - [79]
Ziogou A, Giannakodimos A, Giannakodimos I et al.. “Pandoraea Infections in Humans-A Systematic Review.” Journal of clinical medicine (2024). PMID: 39598047 ↗
L4SR_OBSCited in: Microbiology and Pathogenesis - [80]
Ioannou P, Mourati E, Thalasseli Kazali S et al.. “Infective Endocarditis by Fusobacterium Species-A Systematic Review.” Pathogens (Basel, Switzerland) (2025). PMID: 40872339 ↗
L4SR_OBSCited in: Microbiology and Pathogenesis - [81]
Senneby E, Eriksson B, Fagerholm E et al.. “Bacteremia with Aerococcus sanguinicola: Case Series with Characterization of Virulence Properties.” Open forum infectious diseases (2014). PMID: 25734098 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation - [82]
Seidl K, Chen L, Bayer AS et al.. “Relationship of agr expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2011). PMID: 21968365 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [83]
Pericàs JM, Cervera C, Garcia-de-la-Mària C et al.. “Relationship between Vancomycin MIC and Virulence Gene Expression in Clonal Complexes of Methicillin-Susceptible Staphylococcus aureus Strains Isolated from Left-Sided Endocarditis.” Antimicrobial agents and chemotherapy (2020). PMID: 31907181 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification - [84]
Teles C, Smith A, Lang S. “Antibiotic modulation of the plasminogen binding ability of viridans group streptococci.” Antimicrobial agents and chemotherapy (2011). PMID: 22037854 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Complications - [85]
Kelly MC, Yeager SD, Shorman MA et al.. “Incidence and Predictors of Gram-Negative Bacilli in Hospitalized People Who Inject Drugs with Injection Drug Use-Attributable Infections.” Antimicrobial agents and chemotherapy (2021). PMID: 34543093 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [86]
Abdelhady W, Chen L, Bayer AS et al.. “Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.” The Journal of antimicrobial chemotherapy (2015). PMID: 25564565 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History - [87]
Millar BC, Prendergast BD, Moore JE. “Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis.” The Journal of antimicrobial chemotherapy (2007). PMID: 17962214 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prevention, Infection Control and Special Populations - [88]
Holden E, Bashir A, Das I et al.. “Staphylococcus aureus bacteraemia in a UK tertiary referral centre: a 'transoesophageal echocardiogram for all' policy.” The Journal of antimicrobial chemotherapy (2014). PMID: 24677159 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation - [89]
de Waha S, Noack T, Kister T et al.. “Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection.” Annals of cardiothoracic surgery (2026). PMID: 42292592 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation - [90]
Bamrung V, Sitthicharoenchai P. “The evolving story of Streptococcus gallolyticus: classification, pathogenesis, role in human and animal disease, and laboratory diagnostics.” Frontiers in microbiology (2026). PMID: 41756132 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [91]
Bonaventura A, Del Buono MG, Golino M et al.. “Therapeutic management of inflammatory heart diseases.” Pharmacology & therapeutics (2026). PMID: 41621731 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [92]
Monardo R, Papaioannu Borjesson R, Ponta G et al.. “Epidemiology, Pathogenesis, Clinical Features, and Management of Non-HACEK Gram-Negative Infective Endocarditis.” Antibiotics (Basel, Switzerland) (2025). PMID: 41148672 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [93]
Mulliken JS, Bainbridge ED. “Infective Endocarditis.” The Medical clinics of North America (2025). PMID: 40185554 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [94]
Rapti V, Giannitsioti E, Spernovasilis N et al.. “The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.” Journal of clinical medicine (2025). PMID: 40142895 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [95]
Limonta S, Cambau E, Erpelding ML et al.. “Infective Endocarditis Related to Unusual Microorganisms: A Prospective Population-Based Study.” Open forum infectious diseases (2020). PMID: 32420404 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [96]
Go JR, Challener D, Corsini Campioli C et al.. “Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle.” Open forum infectious diseases (2021). PMID: 35071685 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification - [97]
Leahey PA, LaSalvia MT, Rosenthal ES et al.. “High Morbidity and Mortality Among Patients With Sentinel Admission for Injection Drug Use-Related Infective Endocarditis.” Open forum infectious diseases (2019). PMID: 30949535 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [98]
Huang G, Barnes EW, Peacock JE. “Repeat Infective Endocarditis in Persons Who Inject Drugs: "Take Another Little Piece of my Heart".” Open forum infectious diseases (2018). PMID: 30555849 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [99]
Toivonen F, Sunnerhagen T, Lundin J et al.. “Non-β-hemolytic Streptococcal Bacteremia in Patients With Heart Valve Prosthesis-Is It Always Infective Endocarditis?” Open forum infectious diseases (2025). PMID: 40337722 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Definitive Therapy, Duration and De-escalation - [100]
Hall R, Shaughnessy M, Boll G et al.. “Drug Use and Postoperative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30590480 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [101]
Gomes A, Glaudemans AWJM, Touw DJ et al.. “Diagnostic value of imaging in infective endocarditis: a systematic review.” The Lancet. Infectious diseases (2016). PMID: 27746163 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [102]
Sandoe JA, Barlow G, Chambers JB et al.. “Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE).” The Journal of antimicrobial chemotherapy (2014). PMID: 25355810 ↗
L1GUIDELINECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [103]
Vähäsarja N, Lund B, Ternhag A et al.. “Infective Endocarditis Among High-risk Individuals Before and After the Cessation of Antibiotic Prophylaxis in Dentistry: A National Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35134867 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations - [104]
Kang DH, Kim YJ, Kim SH et al.. “Early surgery versus conventional treatment for infective endocarditis.” The New England journal of medicine (2012). PMID: 22738096 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prognosis and Natural History - [105]
Silverman M, Slater J, Jandoc R et al.. “Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study.” The Lancet. Infectious diseases (2020). PMID: 31981474 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications - [106]
Limeres Posse J, Álvarez Fernández M, Fernández Feijoo J et al.. “Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial.” The Journal of antimicrobial chemotherapy (2016). PMID: 27029851 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations - [107]
Rehm S, Campion M, Katz DE et al.. “Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.” The Journal of antimicrobial chemotherapy (2009). PMID: 19264792 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [108]
Claeys KC, Zasowski EJ, Casapao AM et al.. “Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.” Antimicrobial agents and chemotherapy (2016). PMID: 27431221 ↗
L3TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [109]
Thompson GR, Jenks JD, Baddley JW et al.. “Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.” Clinical microbiology reviews (2023). PMID: 37439685 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [110]
Dagher MM, Eichenberger EM, Addae-Konadu KL et al.. “Maternal and Fetal Outcomes Associated With Infective Endocarditis in Pregnancy.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34111290 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations - [111]
Kinamon T, Dagher M, Park L et al.. “Risk Factors and Outcomes of Hematogenous Vertebral Osteomyelitis in Patients With Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37747828 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [112]
Gonsalves GS, Paltiel AD, Thornhill T et al.. “Patterns of Infectious Disease Associated With Injection Drug Use in Massachusetts.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36757712 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [113]
Calderón-Parra J, Domínguez F, González-Rico C et al.. “Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.” Open forum infectious diseases (2024). PMID: 38500574 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Prognosis and Natural History - [114]
Carugati M, Petti CA, Arnold C et al.. “Antistaphylococcal β-Lactams versus Vancomycin for Treatment of Infective Endocarditis Due to Methicillin-Susceptible Coagulase-Negative Staphylococci: a Prospective Cohort Study from the International Collaboration on Endocarditis.” Antimicrobial agents and chemotherapy (2016). PMID: 27527083 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [115]
Carugati M, Bayer AS, Miró JM et al.. “High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.” Antimicrobial agents and chemotherapy (2013). PMID: 24080644 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [116]
Li M, Kim JB, Sastry BKS et al.. “Infective endocarditis.” Lancet (London, England) (2024). PMID: 39067905 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management - [117]
Thuny F, Grisoli D, Collart F et al.. “Management of infective endocarditis: challenges and perspectives.” Lancet (London, England) (2012). PMID: 22317840 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Complications, Prognosis and Natural History - [118]
Talha KM, Dayer MJ, Thornhill MH et al.. “Temporal Trends of Infective Endocarditis in North America From 2000 to 2017-A Systematic Review.” Open forum infectious diseases (2021). PMID: 35224128 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [119]
Berge A, Kronberg K, Sunnerhagen T et al.. “Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Cohort Study.” Open forum infectious diseases (2019). PMID: 31667201 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [120]
Wang A, Gaca JG, Chu VH. “Management Considerations in Infective Endocarditis: A Review.” JAMA (2018). PMID: 29971402 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention, Infection Control and Special Populations - [121]
Hannachi N, Mariotti A, Camoin-Jau L. “The Potential Role of Statins in Infective Endocarditis: A Meta-Analysis.” Current vascular pharmacology (2026). PMID: 41926297 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [122]
Escolà-Vergé L, Rello P, Declerck C et al.. “Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series.” The Journal of antimicrobial chemotherapy (2022). PMID: 35962570 ↗
L4CASE_REPORTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations - [123]
Dayer MJ, Jones S, Prendergast B et al.. “Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis.” Lancet (London, England) (2014). PMID: 25467569 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prevention, Infection Control and Special Populations - [124]
Bakewell N, Bouck Z, Greenwald ZR et al.. “Recent hydromorphone injection and risk of incident infective endocarditis among people who inject drugs in Toronto, Canada: a cohort study.” Harm reduction journal (2026). PMID: 42321840 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [125]
Jespersen FVB, Jensen SS, Markvart M et al.. “Infective endocarditis and post-treatment bacteremia caused by oral microorganisms: a retrospective cohort study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42142250 ↗
L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management - [126]
Zhang X, Shi Y, Yang Y. “The influence of the IKAP nursing model on wound healing following vacuum sealing drainage in acute infective endocarditis: a retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 41890872 ↗
L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications - [127]
Brioschi G, Mariani S, Occhino G et al.. “Variables associated with diagnostic delay and mortality in infective endocarditis: an observational retrospective study.” International journal of cardiology (2026). PMID: 41871785 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prognosis and Natural History - [128]
Krymko H, Abelson N, El Mahdi N et al.. “Predictors of definite and possible infective endocarditis in children with bacteremia: a reginal cohort study.” European journal of pediatrics (2026). PMID: 41866405 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications - [129]
Jang DH, Kim DH, Choi ES et al.. “Risk Factors for Infective Endocarditis in Contegra Grafts Used as Right Ventricle-Pulmonary Artery Conduits: A Retrospective Cohort Study.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 41826791 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [130]
Lafta MBA, Alhakak A, Østergaard L et al.. “Extraction and reimplantation of cardiac implantable electronic devices in patients with non-surgically treated infective endocarditis: a nationwide cohort study.” European heart journal open (2026). PMID: 41743286 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [131]
Ruffier d'Epenoux L, Fayoux E, Laurent F et al.. “Staphylococcus succinus Infective Endocarditis, France.” Emerging infectious diseases (2024). PMID: 38407206 ↗
L4CASE_REPORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [132]
Karthikeyan G, Ntsekhe M, Islam S et al.. “Mortality and Morbidity in Adults With Rheumatic Heart Disease.” JAMA (2024). PMID: 38837131 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations - [133]
Athan E, Chu VH, Tattevin P et al.. “Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices.” JAMA (2012). PMID: 22535857 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [134]
Regueiro A, Linke A, Latib A et al.. “Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death.” JAMA (2016). PMID: 27623462 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [135]
Jung J, Lee J, Yu SN et al.. “Incidence and Risk Factors of Ocular Infection Caused by Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 26824952 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [136]
Falcone M, Tiseo G, Durante-Mangoni E et al.. “Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort.” Antimicrobial agents and chemotherapy (2018). PMID: 29378721 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [137]
Brown J, Brown K, Forrest A. “Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.” Antimicrobial agents and chemotherapy (2011). PMID: 22123681 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Complications - [138]
Fernandez J, Abbanat D, Shang W et al.. “Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2012). PMID: 22232278 ↗
L5OTHERCited in: Epidemiology, Transmission and Risk Factors - [139]
Casapao AM, Davis SL, McRoberts JP et al.. “Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2014). PMID: 24890596 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [140]
Bae J, Park JH, Lee M et al.. “Clinicomicrobiological risk factors for infective endocarditis in viridans group streptococci bacteraemia.” The Journal of antimicrobial chemotherapy (2024). PMID: 38973607 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [141]
Thornhill MH, Dayer MJ, Prendergast B et al.. “Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis.” The Journal of antimicrobial chemotherapy (2015). PMID: 25925595 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Prevention, Infection Control and Special Populations - [142]
Villamarín M, Fernández-Hidalgo N, Viñado B et al.. “Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.” The Journal of antimicrobial chemotherapy (2024). PMID: 39158195 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [143]
Escrihuela-Vidal F, Fernández-Hidalgo N, Muñoz P et al.. “Infective endocarditis caused by penicillin-resistant viridans group streptococci: a series of nine cases from a Spanish cohort.” The Journal of antimicrobial chemotherapy (2024). PMID: 39351977 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [144]
Sheehy J, Scott AP, Henden AS et al.. “Low rates of complications and β-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy.” The Journal of antimicrobial chemotherapy (2024). PMID: 38973602 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Complications - [145]
Bayless DR, Baddour LM, Lahr BD et al.. “A 5-Year Epidemiological Study of Monomicrobial Enterococcal Bloodstream Infection in a Population-Based Cohort.” Open forum infectious diseases (2025). PMID: 40926878 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [146]
McHugh JW, Talha KM, Baddour LM et al.. “Bloodstream Infection Following Cardiac Valve Repair: A Population-Based Study.” Open forum infectious diseases (2021). PMID: 34938821 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [147]
Virk A, Schutte KM, Steckelberg JM et al.. “End-of-Therapy Echocardiography May Not Be Needed in All in Patients With Endocarditis.” Open forum infectious diseases (2020). PMID: 32211446 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [148]
DeSimone DC, Lahr BD, Anavekar NS et al.. “Temporal Trends of Infective Endocarditis in Olmsted County, Minnesota, Between 1970 and 2018: A Population-Based Analysis.” Open forum infectious diseases (2021). PMID: 33728357 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations - [149]
Nenninger EK, Carwile JL, Ahrens KA et al.. “Rural-Urban Differences in Hospitalizations for Opioid Use-Associated Infective Endocarditis in the United States, 2003-2016.” Open forum infectious diseases (2020). PMID: 32123692 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [150]
Ghanem-Zoubi N, Paul M, Szwarcwort M et al.. “Screening for Q Fever in Patients Undergoing Transcatheter Aortic Valve Implantation, Israel, June 2018-May 2020.” Emerging infectious diseases (2021). PMID: 34287127 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [151]
Stavropoulou E, Guery B, Tzimas G et al.. “Eyes Wide Shut: A Cohort Study Questioning the Role of Fundoscopy in Infective Endocarditis Diagnosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38330299 ↗
L2COHORTCited in: Clinical Presentation - [152]
Peichl Chair P, Tzeis Co-Chair S, Skowronska M et al.. “Intracardiac Echocardiography during Invasive Electrophysiological Procedures: a Scientific Statement of the European Heart Rhythm Association of the ESC, and the European Association of Percutaneous Cardiovascular Interventions of the ESC.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 41973950 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation - [153]
Papadimitriou-Olivgeris M, Guery B, Ianculescu N et al.. “Role of Cerebral Imaging on Diagnosis and Management in Patients With Suspected Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36999313 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup - [154]
Alonso-Menchén D, Marín-Arriaza M, Villamarín M et al.. “Cutibacterium Species Valvular and Cardiac Device-Related Infective Endocarditis: Contemporary Data From the GAMES Prospective Cohort (2008-2023).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38913722 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup - [155]
van der Vaart TW, Prins JM, Soetekouw R et al.. “Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34272564 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup - [156]
Mangner N, Panagides V, Del Val D et al.. “Incidence, Clinical Characteristics, and Impact of Absent Echocardiographic Signs in Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36331961 ↗
L3OTHERCited in: Clinical Presentation, Severity Assessment and Risk Stratification - [157]
Meena DS, Kumar D, Bohra GK et al.. “Nontuberculous Mycobacterial Infective Endocarditis: A Systematic Review of Clinical Characteristics and Outcomes.” Open forum infectious diseases (2024). PMID: 39660020 ↗
L4SR_OBSCited in: Clinical Presentation, Empiric and Acute Management - [158]
El Sabbagh A, Yucel E, Sethi SS et al.. “Percutaneous Mechanical Aspiration in Patients With Right-Sided Infective Endocarditis: A Science Advisory From the American Heart Association.” Journal of the American Heart Association (2026). PMID: 42095279 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [159]
Boyanton BL, Boamah H, Lauter CB. “Native vs Prosthetic Valve Histoplasma capsulatum Infective Endocarditis: A Case Report and Systemic Literature Review Comparing Patient Presentation, Treatment Modalities, Clinical Outcomes, and Diagnostic Laboratory Testing.” Open forum infectious diseases (2021). PMID: 34381842 ↗
L4CASE_REPORTCited in: Clinical Presentation, Empiric and Acute Management - [160]
Holland TL, Arnold C, Fowler VG. “Clinical management of Staphylococcus aureus bacteremia: a review.” JAMA (2014). PMID: 25268440 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [161]
Delaunay M, Gravey F, Join-Lambert O et al.. “Phenotypic and genotypic characterization of clinical Staphylococcus lugdunensis isolates: a French retrospective cohort study.” Microbiology spectrum (2026). PMID: 42339957 ↗
L3COHORTCited in: Clinical Presentation, Antimicrobial Resistance and Stewardship - [162]
Traver EC, Saharia K, Luethy P et al.. “Severe Infective Endocarditis Caused by Bartonella rochalimae.” Emerging infectious diseases (2023). PMID: 38270167 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [163]
Mustafa-Hellou M, Sagi N, Ofran Y et al.. “Endovascular Infection with Kingella kingae Complicated by Septic Arthritis in Immunocompromised Adult Patient.” Emerging infectious diseases (2020). PMID: 33219654 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations - [164]
Shah SU, Xiong YQ, Abdelhady W et al.. “Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.” Antimicrobial agents and chemotherapy (2020). PMID: 32340988 ↗
L5OTHERCited in: Clinical Presentation - [165]
Joseph JP, Meddows TR, Webster DP et al.. “Prioritizing echocardiography in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2012). PMID: 23111851 ↗
L3OTHERCited in: Clinical Presentation, Complications - [166]
Simos PA, Holland DJ, Stewart A et al.. “Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2022). PMID: 35425988 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications - [167]
Richet H, Casalta JP, Thuny F et al.. “Development and assessment of a new early scoring system using non-specific clinical signs and biological results to identify children and adult patients with a high probability of infective endocarditis on admission.” The Journal of antimicrobial chemotherapy (2008). PMID: 18952617 ↗
L3OTHERCited in: Clinical Presentation - [168]
Pranevičius R, Ordienė R, Kmitaitė S et al.. “Vacuum-Assisted Percutaneous Management of Cardiac Implantable Electronic Device Lead Endocarditis.” Journal of clinical medicine (2026). PMID: 42279137 ↗
L4REVIEW_NARRATIVECited in: Clinical Presentation - [169]
Bertolino L, Gallo R, Peluso AMC et al.. “Whipple's endocarditis and biologic response modifiers: a case-based review of an intricate host-pathogen interaction.” Infection (2026). PMID: 42234338 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup - [170]
Jordal S, Dingen H, Wasim D et al.. “Infective endocarditis after transcatheter aortic valve implantation: risk factors and mortality impact in a case-control study.” Open heart (2026). PMID: 42161428 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification - [171]
Bulten BF, Slart RHJA, Glaudemans AWJM et al.. “Standardization of infection [18F]FDG-PET/CT imaging protocols and reporting criteria.” Seminars in nuclear medicine (2026). PMID: 41968012 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [172]
Matei A, Tinică G, Bacușcă A et al.. “Changing Epidemiology, Healthcare-Associated Infections, and Outcomes in Infective Endocarditis: A Five-Year Retrospective Study from a Tertiary Cardiovascular Center.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356041 ↗
L3COHORTCited in: Clinical Presentation, Empiric and Acute Management, Complications - [173]
Fernández Hidalgo N, Gharamti AA, Aznar ML et al.. “Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort.” Open forum infectious diseases (2020). PMID: 32462042 ↗
L2OTHERCited in: Clinical Presentation - [174]
Antonello RM, Canetti D, Riccardi N. “Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.” The Journal of antimicrobial chemotherapy (2022). PMID: 36227704 ↗
L5SR_OBSCited in: Diagnosis and Workup - [175]
Beganovic M, Luther MK, Rice LB et al.. “A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29390132 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications - [176]
Karmarkar EN, Fitzpatrick T, Himmelfarb ST et al.. “Cluster of Nontoxigenic Corynebacterium diphtheriae Infective Endocarditis and Rising Background C. diphtheriae Cases-Seattle, Washington, 2020-2023.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38381586 ↗
L4OTHERCited in: Diagnosis and Workup - [177]
Hajduczenia MM, Klefisch FR, Hopf AGM et al.. “New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging by FISHseq Diagnostics.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36318608 ↗
L3OTHERCited in: Diagnosis and Workup - [178]
Houhamdi Hammou L, Benito Y, Boibieux A et al.. “Malassezia restricta: An Underdiagnosed Causative Agent of Blood Culture-Negative Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34009270 ↗
L3OTHERCited in: Diagnosis and Workup - [179]
Crotty M, Devall H, Cook N et al.. “Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia.” Open forum infectious diseases (2024). PMID: 39257675 ↗
L3TRIAL_NONRANDOMCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [180]
Kim M, Damronglerd P, Molina Garcia S et al.. “Illuminating the Challenges and Diagnostic Utility of Plasma Microbial Cell-Free DNA Sequencing in Suspected Infective Endocarditis: A Retrospective Observational Cohort Study.” Open forum infectious diseases (2025). PMID: 40046887 ↗
L3COHORTCited in: Diagnosis and Workup - [181]
Werneburg LI, Schweyen R, Delank KS et al.. “Dental Consultation in Initially Unknown-Source Staphylococcus aureus Bacteremia: A Retrospective Single-Center Cohort Study.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353670 ↗
L3COHORTCited in: Diagnosis and Workup, Empiric and Acute Management - [182]
Cafardi JM, Haas D, Lamarre T et al.. “Brucella Endocarditis in Persons Who Inject Drugs.” Open forum infectious diseases (2020). PMID: 32280723 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [183]
Babiker A, El Hag MI, Perez C. “Bartonella Infectious Endocarditis Associated With Cryoglobulinemia and Multifocal Proliferative Glomerulonephritis.” Open forum infectious diseases (2018). PMID: 30151411 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [184]
Ramakrishnan G, Kronig I, Gaïa N et al.. “Mycoplasma genitalium Endocarditis in Prosthetic Aortic Valve.” Emerging infectious diseases (2023). PMID: 37735787 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [185]
Ersoy SC, Abdelhady W, Li L et al.. “Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.” Antimicrobial agents and chemotherapy (2019). PMID: 31010857 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [186]
Fang Y, Kirsch JR, Li L et al.. “Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.” Antimicrobial agents and chemotherapy (2021). PMID: 33318001 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [187]
Ersoy SC, Proctor RA, Rose WE et al.. “Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine.” Antimicrobial agents and chemotherapy (2024). PMID: 38349162 ↗
L5OTHERCited in: Diagnosis and Workup - [188]
Mishra NN, Abdelhady W, Elsayed AM et al.. “Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance.” Antimicrobial agents and chemotherapy (2023). PMID: 36877026 ↗
L5OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [189]
Ortiz de la Rosa JM, Martín-Gutiérrez G, Casimiro-Soriguer CS et al.. “C-terminal deletion of RelA protein is suggested as a possible cause of infective endocarditis recurrence with Enterococcus faecium.” Antimicrobial agents and chemotherapy (2024). PMID: 38349158 ↗
L4OTHERCited in: Diagnosis and Workup, Prognosis and Natural History - [190]
Garcia-de-la-Maria C, Xiong YQ, Pericas JM et al.. “Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.” Antimicrobial agents and chemotherapy (2017). PMID: 28264848 ↗
L5OTHERCited in: Diagnosis and Workup - [191]
LaPlante KL, Woodmansee S. “Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.” Antimicrobial agents and chemotherapy (2009). PMID: 19564363 ↗
L5OTHERCited in: Diagnosis and Workup - [192]
Luther MK, Arvanitis M, Mylonakis E et al.. “Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.” Antimicrobial agents and chemotherapy (2014). PMID: 24867993 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Natural History - [193]
Brown E, Gould FK. “Oral antibiotics for infective endocarditis: a clinical review.” The Journal of antimicrobial chemotherapy (2020). PMID: 32240296 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [194]
Moretó-Castellsagué C, González-Díaz A, Escrihuela-Vidal F et al.. “In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization.” The Journal of antimicrobial chemotherapy (2025). PMID: 40693491 ↗
L4OTHERCited in: Diagnosis and Workup - [195]
Cañas MA, Cuervo G, García-González J et al.. “In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis.” The Journal of antimicrobial chemotherapy (2026). PMID: 41342135 ↗
L4OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [196]
Lalanne S, Cattoir V, Guerin F et al.. “Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.” The Journal of antimicrobial chemotherapy (2023). PMID: 37248684 ↗
L5OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [197]
Westbrook KJ, Chilambi GS, Stellfox ME et al.. “Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.” The Journal of antimicrobial chemotherapy (2024). PMID: 38334390 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Antimicrobial Resistance and Stewardship - [198]
Stavropoulou E, Ledergerber B, Fourré N et al.. “Infective Endocarditis and Antimicrobial Timing: A Case for Delay?” Open forum infectious diseases (2025). PMID: 41141452 ↗
L3OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Prognosis and Natural History - [199]
Boodman C, Fongwen N, Pecoraro AJ et al.. “Hidden Burden of Bartonella quintana on the African Continent: Should the Bacterial Infection Be Considered a Neglected Tropical Disease?” Open forum infectious diseases (2023). PMID: 38370291 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [200]
Guimaraes AO, Gutierrez J, Maskarinec SA et al.. “Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 31041341 ↗
L3OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification - [201]
El Zein S, Challener DW, Ranganath N et al.. “Acute Coxiella burnetii Infection: A 10-Year Clinical Experience at a Tertiary Care Center in the United States.” Open forum infectious diseases (2024). PMID: 38868311 ↗
L4OTHERCited in: Diagnosis and Workup, Prevention, Infection Control and Special Populations - [202]
Bouchiat C, Saison J, Boisset S et al.. “Nontuberculous Mycobacteria: An Underestimated Cause of Bioprosthetic Valve Infective Endocarditis.” Open forum infectious diseases (2015). PMID: 26213691 ↗
L4OTHERCited in: Diagnosis and Workup - [203]
Fourré N, Zimmermann V, Ianculescu N et al.. “Evaluating Blood Culture Parameters to Identify Patients at Low Risk of Infective Endocarditis Among Those With Bacteremia by Gram-positive Cocci.” Open forum infectious diseases (2025). PMID: 40908972 ↗
L3OTHERCited in: Diagnosis and Workup - [204]
Wo S, Dubrovskaya Y, Siegfried J et al.. “Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia.” Open forum infectious diseases (2020). PMID: 33511221 ↗
L3OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications - [205]
Peng Q, Lin Y. “A case report of infective endocarditis caused by Mycoplasma pneumoniae in a child.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42053852 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation - [206]
Hua M, Sun J, Wang Y et al.. “A patient with aortic annular rupture secondary to blood culture-negative endocarditis: A case report.” Frontiers in cardiovascular medicine (2026). PMID: 41982218 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [207]
Liu J, Wu R. “Intraoperative sampling for postoperative metagenomic next-generation sequencing to guide biofilm-targeted therapy for Cutibacterium acnes infective endocarditis complicated by ruptured sinus of Valsalva aneurysm: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 41869518 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation - [208]
Gray K, Ahad F, Cunnington A. “Transthoracic echocardiography in children with Staphylococcus aureus bacteraemia: a multi-centre retrospective analysis.” BMJ paediatrics open (2026). PMID: 42320931 ↗
L2OTHERCited in: Diagnosis and Workup - [209]
Wehage P, Fuge J, Hilberink L et al.. “Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort.” Infection (2026). PMID: 42307837 ↗
L3OTHERCited in: Diagnosis and Workup - [210]
Klein CF, Gørtz S, Wohlfahrt J et al.. “Long-term Risk of Hemorrhagic Stroke in Patients With Infective Endocarditis: A Danish Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 29920590 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [211]
Panagides V, Del Val D, Abdel-Wahab M et al.. “Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34894124 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [212]
Hémar V, Camou F, Roubaud-Baudron C et al.. “The Mortality of Infective endocarditis with and without Surgery in Elderly (MoISE) Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37369092 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [213]
Lecomte R, Issa N, Gaborit B et al.. “Risk-benefit Assessment of Systematic Thoracoabdominal-pelvic Computed Tomography in Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30615098 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [214]
Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Characteristics and Outcome of Acute Heart Failure in Infective Endocarditis: Focus on Cardiogenic Shock.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33560404 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [215]
Fernández-Hidalgo N, Almirante B, Tornos P et al.. “Contemporary epidemiology and prognosis of health care-associated infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18834314 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [216]
García-Granja PE, López J, Vilacosta I et al.. “Impact of Valve Culture in the Prognosis of Active Left-sided Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107544 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [217]
Dahl A, Lauridsen TK, Arpi M et al.. “Risk Factors of Endocarditis in Patients With Enterococcus faecalis Bacteremia: External Validation of the NOVA Score.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27307506 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [218]
Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Outcomes and Risk Factors of Septic Shock in Patients With Infective Endocarditis: A Prospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34189153 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [219]
Escrihuela-Vidal F, López-Cortés LE, Escolà-Vergé L et al.. “Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study.” Open forum infectious diseases (2021). PMID: 34189163 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [220]
Wang R, Zhang H, Ye M et al.. “Meta-analysis of valved conduits in right ventricular outflow tract reconstruction: comparison of homograft, bovine jugular vein, and EPTFE valved conduits.” International journal of surgery (London, England) (2026). PMID: 41556161 ↗
L1SR_OBSCited in: Severity Assessment and Risk Stratification - [221]
Meena DS, Kumar D, Bohra GK et al.. “Clinical outcomes in blood culture-negative versus blood culture-positive infective endocarditis: a systematic review and meta-analysis.” Heart (British Cardiac Society) (2025). PMID: 41249039 ↗
L1SR_OBSCited in: Severity Assessment and Risk Stratification - [222]
Cai Z, Song T, Qiu S et al.. “Nomogram for predicting 30-day mortality in patients with infective endocarditis: a retrospective study.” BMC medical informatics and decision making (2026). PMID: 41917954 ↗
L3COHORTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [223]
Martiny SK, Schmidt M, Povlsen JA et al.. “Socioeconomic disparities in long-term mortality after infective endocarditis in Denmark: a nationwide cohort study.” The Lancet regional health. Europe (2025). PMID: 41510143 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [224]
Armange L, Blanc Petitjean P, Le Bot A et al.. “Preoperative coronary evaluation in valve surgery for infective endocarditis: findings from a multicenter retrospective study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 41283954 ↗
L3COHORTCited in: Severity Assessment and Risk Stratification - [225]
Hong M, Xiang W, Kong L et al.. “Corynebacterium Striatum Infective Endocarditis: A Systematic Review.” Journal of inflammation research (2025). PMID: 41403720 ↗
L5SR_OBSCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship - [226]
Scheggi V, Stefàno PL. “Sex-related differences in infective endocarditis. A retrospective study in a high-volume surgical centre.” Heart & lung : the journal of critical care (2026). PMID: 41512348 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [227]
Ruch Y, Mazzucotelli JP, Lefebvre F et al.. “Impact of Setting up an "Endocarditis Team" on the Management of Infective Endocarditis.” Open forum infectious diseases (2019). PMID: 31660397 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification, Complications, Prognosis and Natural History - [228]
Hernández-Meneses M, Llopis J, Sandoval E et al.. “Forty-Year Trends in Cardiac Implantable Electronic Device Infective Endocarditis.” Open forum infectious diseases (2022). PMID: 36381626 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [229]
Freling S, Wald-Dickler N, Banerjee J et al.. “Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36881940 ↗
L2COHORTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History - [230]
Robson C, Tan B, Stuart R et al.. “A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36691839 ↗
L5SR_OBSCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [231]
Rallet B, Pouy R, Coutureau C et al.. “Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40823988 ↗
L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [232]
Danneels P, Hamel JF, Picard L et al.. “Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36124844 ↗
L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [233]
Goff DA, Mangino JE, Glassman AH et al.. “Review of Guidelines for Dental Antibiotic Prophylaxis for Prevention of Endocarditis and Prosthetic Joint Infections and Need for Dental Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31728507 ↗
L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations - [234]
Frondizi F, Leanza GM, Chiuchiarelli M et al.. “The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp.” Open forum infectious diseases (2025). PMID: 40799789 ↗
L4TRIAL_NONRANDOMCited in: Empiric and Acute Management - [235]
Katragadda S, Baddour LM, Chesdachai S et al.. “Postoperative Treatment Regimens in Patients With Native Valve Endocarditis due to Staphylococcus aureus Who Undergo Valve Replacement or Repair.” Open forum infectious diseases (2025). PMID: 40207048 ↗
L2TRIAL_NONRANDOMCited in: Empiric and Acute Management, Complications - [236]
Jordan H, Kozierowski K, Pickles R et al.. “Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study.” Open forum infectious diseases (2025). PMID: 40657166 ↗
L4TRIAL_NONRANDOMCited in: Empiric and Acute Management - [237]
Duval X, Leport C. “Prophylaxis of infective endocarditis: current tendencies, continuing controversies.” The Lancet. Infectious diseases (2008). PMID: 18353264 ↗
L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations - [238]
Cairns KA, Udy AA, Peel TN et al.. “Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.” Clinical microbiology reviews (2023). PMID: 37067406 ↗
L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [239]
Rebechi MT, Heil EL, Luethy PM et al.. “Streptococcus pyogenes Infective Endocarditis-Association With Injection Drug Use: Case Series and Review of the Literature.” Open forum infectious diseases (2021). PMID: 34262985 ↗
L4CASE_REPORTCited in: Empiric and Acute Management - [240]
El-Dalati S, Castillo MRC, Strnad L et al.. “Shared Decision-Making for Partial Oral Antibiotic Treatment of Infective Endocarditis: A Case Series.” Open forum infectious diseases (2024). PMID: 38585184 ↗
L4CASE_REPORTCited in: Empiric and Acute Management - [241]
Herrera-Hidalgo L, López-Cortes LE, Luque-Márquez R et al.. “Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy.” Antimicrobial agents and chemotherapy (2020). PMID: 32393486 ↗
L5OTHERCited in: Empiric and Acute Management - [242]
García-de-la-Mària C, Marco F, Armero Y et al.. “Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.” Antimicrobial agents and chemotherapy (2010). PMID: 20421394 ↗
L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [243]
Marco F, de la Mària CG, Armero Y et al.. “Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2008). PMID: 18426900 ↗
L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation - [244]
Tana C, Moffa L, Tana M et al.. “Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies.” Microorganisms (2026). PMID: 42197456 ↗
L2SR_OBSCited in: Empiric and Acute Management - [245]
Ren S, Zhang L, Zhai Y et al.. “Clinical Features and Outcomes of Surgically Treated Infective Endocarditis in Adults with and Without Congenital Heart Disease: A 12-Year Cohort Study.” Journal of cardiovascular development and disease (2026). PMID: 42346445 ↗
L2COHORTCited in: Empiric and Acute Management - [246]
Webb G, Choi J, Younes A et al.. “Comparing clinical manifestations, treatment strategies and outcomes of Staphylococcus lugdunensis bacteraemia versus Staphylococcus aureus bacteraemia - a retrospective cohort study.” Internal medicine journal (2026). PMID: 42250238 ↗
L2COHORTCited in: Empiric and Acute Management - [247]
Festou B, Tchalla A. “Therapeutic drug monitoring in older adults treated with beta-lactams or daptomycin in a French tertiary hospital: A retrospective study (TEldBet).” Infectious diseases now (2026). PMID: 42140588 ↗
L2COHORTCited in: Empiric and Acute Management - [248]
Combs T, Stoner BJ, McCoy P et al.. “Invasive Candida Infection in Patients With Bacterial Infective Endocarditis.” Open forum infectious diseases (2024). PMID: 38595952 ↗
L4OTHERCited in: Empiric and Acute Management - [249]
Pericàs JM, Llopis J, Muñoz P et al.. “Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria.” Open forum infectious diseases (2022). PMID: 36172059 ↗
L2OTHERCited in: Empiric and Acute Management - [250]
Rodger L, Shah M, Shojaei E et al.. “Recurrent Endocarditis in Persons Who Inject Drugs.” Open forum infectious diseases (2019). PMID: 31660358 ↗
L2OTHERCited in: Empiric and Acute Management - [251]
Abulimiti K, Yiming N, Zou Q et al.. “Native Aortic and Mitral Valve Endocarditis Caused by Brucella: A Rare Case Report and Systematic Review.” Cardiology in review (2026). PMID: 42308361 ↗
L4SR_OBSCited in: Empiric and Acute Management - [252]
Alhafez H, Ahmad OM, Kananyan M et al.. “Intracranial mycotic aneurysms in pediatric patients: A systematic review.” Surgical neurology international (2026). PMID: 42116912 ↗
L4SR_OBSCited in: Empiric and Acute Management - [253]
Pericà S JM, Llopis J, González-Ramallo V et al.. “Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30649282 ↗
L2COHORTCited in: Definitive Therapy, Duration and De-escalation - [254]
Corey GR. “Staphylococcus aureus bloodstream infections: definitions and treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374581 ↗
L5CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation - [255]
Vale C, Sime FB, Cotta MO et al.. “Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review.” The Journal of antimicrobial chemotherapy (2026). PMID: 41982169 ↗
L2SR_OBSCited in: Definitive Therapy, Duration and De-escalation, Prognosis and Natural History - [256]
Herrera-Hidalgo L, de Alarcón A, López-Cortes LE et al.. “Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?” Antimicrobial agents and chemotherapy (2020). PMID: 33046488 ↗
L4OTHERCited in: Definitive Therapy, Duration and De-escalation, Complications - [257]
Bellouard R, Rambaud A, Delaunay C et al.. “Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36760090 ↗
L2OTHERCited in: Definitive Therapy, Duration and De-escalation - [258]
Cooper MM, Preslaski CR, Shihadeh KC et al.. “Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review.” Open forum infectious diseases (2021). PMID: 34738025 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy, Duration and De-escalation - [259]
Sekar P, Johnson JR, Thurn JR et al.. “Comparative Sensitivity of Transthoracic and Transesophageal Echocardiography in Diagnosis of Infective Endocarditis Among Veterans With Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2017). PMID: 28470017 ↗
L2OTHERCited in: Definitive Therapy, Duration and De-escalation - [260]
Al Janabi J, El Noaimi M, Sunnerhagen T et al.. “Infective Endocarditis Caused by Non-HACEK Gram-Negative Bacteria, a Registry-Based Comparative Study.” Open forum infectious diseases (2025). PMID: 40059980 ↗
L3OTHERCited in: Definitive Therapy, Duration and De-escalation - [261]
Shah NH, Shutt KA, Doi Y. “Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score-Matched, Retrospective Cohort Analysis.” Open forum infectious diseases (2021). PMID: 34805443 ↗
L2OTHERCited in: Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications - [262]
Assayed A, Aburumman S, Altahhan AH et al.. “Do Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predict In-Hospital and Long-Term Mortality in Endocarditis Patients?: A Systematic Review and Meta-Analysis.” Cardiology in review (2026). PMID: 42361207 ↗
L2SR_OBSCited in: Definitive Therapy, Duration and De-escalation - [263]
Cairns KA, Abbott IJ, Udy AA et al.. “Vancomycin-resistant Enterococcus infective endocarditis: A case series and review of the literature.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42235917 ↗
L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation - [264]
Cojutti PG, Pascale R, Grechi A et al.. “Pharmacokinetic/Pharmacodynamic Analysis of High-Dose Daptomycin in Combination with Continuous Infusion Ceftobiprole in a Case Series of Documented Staphylococcal Bacteremia or Endocarditis: Is There Any Room for TDM-Guided Dosing Reduction?” Antibiotics (Basel, Switzerland) (2026). PMID: 41892476 ↗
L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation - [265]
Wei CY, Lee HC, Liu LT et al.. “Case Report: Native aortic valve Listeria monocytogenes endocarditis in an adult with Evans syndrome.” Frontiers in immunology (2026). PMID: 41822507 ↗
L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations - [266]
Tran LNB, Zhuo R, Singha M et al.. “First reported case of Capnocytophaga cynodegmi infective endocarditis: A diagnostic odyssey.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41619833 ↗
L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation - [267]
Mularoni A, Mikulska M, Barbera F et al.. “Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diagnosis and Targeted Therapy of Infective Endocarditis: A Prospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35686318 ↗
L2COHORTCited in: Antimicrobial Resistance and Stewardship - [268]
Zhang R, Polenakovik H, Barreras Beltran IA et al.. “Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35510938 ↗
L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship - [269]
Fujitani S, Rowlinson MC, George WL. “Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association's Guidelines for the Treatment of Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18444825 ↗
L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship - [270]
Lagier JC, Aubry C, Delord M et al.. “From Expert Protocols to Standardized Management of Infectious Diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28859349 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations - [271]
Knoll B, Tleyjeh IM, Steckelberg JM et al.. “Infective endocarditis due to penicillin-resistant viridans group streptococci.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17516402 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [272]
Naber CK. “Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374578 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations - [273]
Durante-Mangoni E, Casillo R, Bernardo M et al.. “High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 22100575 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [274]
Colin V, Guerpillon B, Blot M et al.. “Infectious endocarditis caused by Elizabethkingia spp.: Two case reports and a literature review.” Journal of infection and public health (2025). PMID: 40915003 ↗
L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship - [275]
El Ghali A, Stamper K, Kunz Coyne AJ et al.. “Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models.” Antimicrobial agents and chemotherapy (2023). PMID: 37877697 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [276]
Banerjee A, Kaplan JB, Soherwardy A et al.. “Characterization of TEM-1 β-Lactamase-Producing Kingella kingae Clinical Isolates.” Antimicrobial agents and chemotherapy (2013). PMID: 23796935 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [277]
Reissier S, Saleh-Mghir A, Guerin F et al.. “In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.” The Journal of antimicrobial chemotherapy (2018). PMID: 29329389 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [278]
Cañas MA, García-González J, Luque-Paz D et al.. “In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance.” The Journal of antimicrobial chemotherapy (2026). PMID: 42017201 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [279]
Kambarev S, Pecorari F, Corvec S. “Novel Tn916-like elements confer aminoglycoside/macrolide co-resistance in clinical isolates of Streptococcus gallolyticus ssp. gallolyticus.” The Journal of antimicrobial chemotherapy (2018). PMID: 29438479 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [280]
Awad AS, Mangold AS, Ainechi A et al.. “Causes, Predictors, and Treatment of Vasoplegia in Cardiac Surgery: A Narrative Review.” Anesthesia and analgesia (2026). PMID: 42268652 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [281]
Ishak A, Qadeer YK, AlRawashdeh MM et al.. “Infective Endocarditis: A Contemporary Review of Epidemiology, Diagnosis, and Management.” Antibiotics (Basel, Switzerland) (2026). PMID: 42192704 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [282]
Meena DS, Kumar D, Bohra GK. “Combination antibiotic therapy in Staphylococcus aureus endocarditis: evidence, controversies, and future directions.” Infection (2026). PMID: 42149364 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [283]
Prezioso A, Pecora D, Dell'Aquila A et al.. “Rethinking Antibiotic Prophylaxis in Femoral-Access Catheter Ablation: A Pragmatic, Risk-Based Proposal.” Journal of clinical medicine (2026). PMID: 41827200 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations - [284]
Ladines-Lim JB, Nemiroff A, Cressman L et al.. “Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023-2024.” Open forum infectious diseases (2026). PMID: 42292776 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [285]
Boleij A, van Gelder MM, Swinkels DW et al.. “Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21960713 ↗
L1SR_OBSCited in: Complications - [286]
Snygg-Martin U, Giang KW, Dellborg M et al.. “Cumulative Incidence of Infective Endocarditis in Patients with Congenital Heart Disease: A Nationwide, Case-Control Study Over Nine Decades.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34036324 ↗
L3CASE_CONTROLCited in: Complications - [287]
Beaumont AL, Mestre F, Decaux S et al.. “Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.” Open forum infectious diseases (2024). PMID: 38737431 ↗
L4TRIAL_NONRANDOMCited in: Complications, Prognosis and Natural History - [288]
Aldrich JB, Madsen N, Armstrong AK et al.. “Evaluation and treatment of infective endocarditis in children and adolescents with underlying CHD: a Paediatric Acute Care Cardiology Collaborative Clinical Practice Guideline.” Cardiology in the young (2025). PMID: 41466172 ↗
L1GUIDELINECited in: Complications - [289]
Jansen JW, Linneman TW, Tan X et al.. “Comparison of Adverse Drug Reactions Between Patients Treated With Ceftaroline or Ceftriaxone: A Single-Center, Matched Cohort Study.” Open forum infectious diseases (2019). PMID: 31281870 ↗
L2COHORTCited in: Complications - [290]
Posner C, Füssl E, Koyun F et al.. “Antithrombotic therapy in infective endocarditis: Long-term clinical outcomes of a retrospective cohort study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 41661255 ↗
L2COHORTCited in: Complications - [291]
Le Banner E, Le Moulec J, Kerjouan M et al.. “A contemporary picture of bacterial infections in patients with hereditary hemorrhagic telangiectasia: A nationwide cohort study.” The Journal of infection (2026). PMID: 41544822 ↗
L2COHORTCited in: Complications, Prevention, Infection Control and Special Populations - [292]
García-de-la-Mària C, Pericas JM, Del Río A et al.. “Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.” Antimicrobial agents and chemotherapy (2013). PMID: 23478959 ↗
L5OTHERCited in: Complications - [293]
Lodise TP, McKinnon PS, Levine DP et al.. “Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2007). PMID: 17664322 ↗
L2OTHERCited in: Complications - [294]
Abdelhady W, Bayer AS, Seidl K et al.. “Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2013). PMID: 23295925 ↗
L5OTHERCited in: Complications - [295]
Bock M, Van Hasselt JGC, Schwartz F et al.. “Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.” The Journal of antimicrobial chemotherapy (2023). PMID: 37823408 ↗
L4OTHERCited in: Complications - [296]
Cerón I, Muñoz P, Marín M et al.. “Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy.” The Journal of antimicrobial chemotherapy (2014). PMID: 24532682 ↗
L2OTHERCited in: Complications - [297]
Ho J, Archuleta S, Sulaiman Z et al.. “Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service.” The Journal of antimicrobial chemotherapy (2010). PMID: 20864497 ↗
L2OTHERCited in: Complications - [298]
Duncan CJ, Barr DA, Ho A et al.. “Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis.” The Journal of antimicrobial chemotherapy (2013). PMID: 23475647 ↗
L2OTHERCited in: Complications - [299]
San-Juan R, Fernández-Ruiz M, Gasch O et al.. “High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2017). PMID: 28379553 ↗
L2OTHERCited in: Complications - [300]
Boccuto F, Barracano R, Guglielmi G et al.. “Transition from Paediatric to Adult Care in Congenital Heart Disease: A Call for Action.” Journal of clinical medicine (2025). PMID: 41464771 ↗
L5REVIEW_NARRATIVECited in: Complications - [301]
Nappi F, Avtaar Singh SS. “Prevalence of healthcare-associated infections in developing and developed countries: a systematic review.” BMC infectious diseases (2026). PMID: 42046010 ↗
L2SR_OBSCited in: Prognosis and Natural History - [302]
Østergaard L, Voldstedlund M, Bruun NE et al.. “Prevalence and Mortality of Infective Endocarditis in Community-Acquired and Healthcare-Associated Staphylococcus aureus Bacteremia: A Danish Nationwide Registry-Based Cohort Study.” Open forum infectious diseases (2022). PMID: 36540385 ↗
L2COHORTCited in: Prognosis and Natural History - [303]
Zasowski EJ, Trinh TD, Claeys KC et al.. “Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.” Open forum infectious diseases (2021). PMID: 35146040 ↗
L2COHORTCited in: Prognosis and Natural History - [304]
Pavia-Velandia PX, Torres-Gómez PL, Molano-González N et al.. “Performance of predictive scores for in-hospital mortality in surgical infective endocarditis: a retrospective cohort study.” Frontiers in cardiovascular medicine (2026). PMID: 42273601 ↗
L2COHORTCited in: Prognosis and Natural History - [305]
García-Álvarez L, Sanz MM, Marín M et al.. “Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish Collaboration on Endocarditis (GAMES) experience.” The Journal of antimicrobial chemotherapy (2019). PMID: 30789210 ↗
L4OTHERCited in: Prognosis and Natural History - [306]
Meyer-Schwickerath C, Schmidt-Hellerau K, Camp J et al.. “Health-Related Quality of Life of Patients With Infective Endocarditis-A Cross-Sectional Study Based on Data From the DERIVE Cohort.” Open forum infectious diseases (2026). PMID: 42182832 ↗
L2OTHERCited in: Prognosis and Natural History - [307]
Duval X, Millot S, Chirouze C et al.. “Oral Streptococcal Endocarditis, Oral Hygiene Habits, and Recent Dental Procedures: A Case-Control Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28369398 ↗
L3CASE_CONTROLCited in: Prevention, Infection Control and Special Populations - [308]
Duval X, Alla F, Hoen B et al.. “Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16705565 ↗
L2OTHERCited in: Prevention, Infection Control and Special Populations - [309]
Pakotiprapha A, Chungsomprasong P, Vijarnsorn C et al.. “Risk of Infective Endocarditis in Pediatric Staphylococcal Bacteremia: A 20-Year Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 42115837 ↗
L2COHORTCited in: Prevention, Infection Control and Special Populations - [310]
Athanassopoulos G, Pefanis A, Sakka V et al.. “Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.” Antimicrobial agents and chemotherapy (2006). PMID: 16436723 ↗
L5OTHERCited in: Prevention, Infection Control and Special Populations - [311]
Robson C, Liu X, Al-Mukhtar O et al.. “Population pharmacokinetics and optimized prophylaxis dosing of cefazolin during transcatheter aortic valve implantation.” The Journal of antimicrobial chemotherapy (2025). PMID: 40177849 ↗
L4OTHERCited in: Prevention, Infection Control and Special Populations - [312]
da Silva Neto MJJ, MacKay G, Agaram R et al.. “Evaluation of amoxicillin, metronidazole and gentamicin dosage regimens for use in antibiotic prophylaxis in colorectal surgery.” The Journal of antimicrobial chemotherapy (2021). PMID: 34542630 ↗
L4OTHERCited in: Prevention, Infection Control and Special Populations - [313]
Grillo S, Isler B, Bonet-Basiero A et al.. “Does Biological Sex Determine the Natural History and Management of Infective Endocarditis?” The Canadian journal of cardiology (2025). PMID: 41197950 ↗
L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations - [314]
Iglesias-Varea J, Kirkegaard-Biosca C, Pizzi MN et al.. “Infective Endocarditis After Transcatheter Aortic Valve Implantation: Current Challenges in Diagnosis, Management, and Prevention.” The Canadian journal of cardiology (2025). PMID: 41177375 ↗
L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations - [315]
Thornhill MH, Dayer MJ, Prendergast BD et al.. “Endocarditis Prophylaxis-Indications, Application and Current Controversies.” The Canadian journal of cardiology (2025). PMID: 41101643 ↗
L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations - [316]
Hindy JR, Chesdachai S, DeSimone DC et al.. “Medical Management in Adult Patients Following Cardiac Valve Surgery for Infective Endocarditis: A Comprehensive Review.” The Canadian journal of cardiology (2025). PMID: 40953817 ↗
L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations - [317]
Latkowska-Wiśniewska M, Jakubowska S, Górski B. “Antibiotics in Mucogingival Surgery for Recession Treatment: A Narrative Review.” Antibiotics (Basel, Switzerland) (2025). PMID: 40867964 ↗
L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations - [318]
Morelli MK, Veve MP, Shorman MA. “Maternal Bacteremia Caused by Staphylococcus Aureus With a Focus on Infective Endocarditis.” Open forum infectious diseases (2020). PMID: 32766382 ↗
L4OTHERCited in: Prevention, Infection Control and Special Populations - [319]
Vyas DA, Marinacci L, Bearnot B et al.. “Creation of a Multidisciplinary Drug Use Endocarditis Treatment (DUET) Team: Initial Patient Characteristics, Outcomes, and Future Directions.” Open forum infectious diseases (2022). PMID: 35252467 ↗
L4OTHERCited in: Prevention, Infection Control and Special Populations - [320]
Suda KJ, Henschel H, Patel U et al.. “Use of Antibiotic Prophylaxis for Tooth Extractions, Dental Implants, and Periodontal Surgical Procedures.” Open forum infectious diseases (2017). PMID: 29326959 ↗
L2OTHERCited in: Prevention, Infection Control and Special Populations - [321]
Weese JS, Soltero-Rivera M, Weese HE et al.. “Infectious complications of dental procedures in dogs and cats, and the impact of antimicrobial prophylaxis: a systematic review.” The Journal of small animal practice (2026). PMID: 42244488 ↗
L5SR_OBSCited in: Prevention, Infection Control and Special Populations - [322]
Loper C, Baskette J, Fagan TR et al.. “Prophylactic Antibiotics for Prevention of Infective Endocarditis or Bacteremia in Pediatric Patients With Congenital Heart Disease Undergoing Dental Procedures: Systematic Review.” Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry (2025). PMID: 41269014 ↗
L2SR_OBSCited in: Prevention, Infection Control and Special Populations - [323]
Zelfani S, Ernandes H, Kaoual S et al.. “Case Report: Austrian syndrome with multifocal septic arthritis in the immunocompetent elderly: expanding the clinical spectrum.” Frontiers in medicine (2026). PMID: 41675630 ↗
L4CASE_REPORTCited in: Prevention, Infection Control and Special Populations